EP2788086B1 - Substituted pyrazoles as mglu5 receptor modulators - Google Patents
Substituted pyrazoles as mglu5 receptor modulators Download PDFInfo
- Publication number
- EP2788086B1 EP2788086B1 EP12808705.3A EP12808705A EP2788086B1 EP 2788086 B1 EP2788086 B1 EP 2788086B1 EP 12808705 A EP12808705 A EP 12808705A EP 2788086 B1 EP2788086 B1 EP 2788086B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- added
- acid
- stirred
- desired product
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003217 pyrazoles Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 87
- 150000003839 salts Chemical class 0.000 claims description 22
- 208000010877 cognitive disease Diseases 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 9
- 208000028017 Psychotic disease Diseases 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 3
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 206010027175 memory impairment Diseases 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 208000022610 schizoaffective disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000000034 method Methods 0.000 description 617
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 189
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 182
- 239000000047 product Substances 0.000 description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- 238000006243 chemical reaction Methods 0.000 description 71
- 239000000203 mixture Substances 0.000 description 65
- 0 *C=C1CC*CC1 Chemical compound *C=C1CC*CC1 0.000 description 63
- 235000019439 ethyl acetate Nutrition 0.000 description 63
- 229940093499 ethyl acetate Drugs 0.000 description 62
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 62
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 39
- 239000003480 eluent Substances 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 32
- 229910002027 silica gel Inorganic materials 0.000 description 32
- 239000003643 water by type Substances 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- 229910052796 boron Inorganic materials 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 25
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 18
- -1 aryl piperazines Chemical class 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 229960004132 diethyl ether Drugs 0.000 description 17
- 229930195712 glutamate Natural products 0.000 description 17
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 16
- 239000012267 brine Substances 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 229960000583 acetic acid Drugs 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000012891 Ringer solution Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 230000003281 allosteric effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 208000020016 psychiatric disease Diseases 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 229940001593 sodium carbonate Drugs 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 5
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- UIMPFLCYHPAILW-UHFFFAOYSA-N 5,6,7,8-tetrahydro-4h-[1,3]thiazolo[4,5-d]azepin-2-amine;hydrobromide Chemical compound Br.C1CNCCC2=C1N=C(N)S2 UIMPFLCYHPAILW-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229960003390 magnesium sulfate Drugs 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 229940093956 potassium carbonate Drugs 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- YPJNFQUWGRVTQI-UHFFFAOYSA-N tert-butyl 4-(6-methoxypyrimidin-4-yl)piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(C2CCN(CC2)C(=O)OC(C)(C)C)=N1 YPJNFQUWGRVTQI-UHFFFAOYSA-N 0.000 description 4
- GDPSCFYDXPEIEE-UHFFFAOYSA-N tert-butyl 4-cyanopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C#N)CC1 GDPSCFYDXPEIEE-UHFFFAOYSA-N 0.000 description 4
- MMDLTXGEZNHAOV-UHFFFAOYSA-N 1,3-bis(4-fluorophenyl)propane-1,3-dione Chemical compound C1=CC(F)=CC=C1C(=O)CC(=O)C1=CC=C(F)C=C1 MMDLTXGEZNHAOV-UHFFFAOYSA-N 0.000 description 3
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- OSINEUGRWRMBIN-UHFFFAOYSA-N 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-5-oxoazepan-4-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC(CC(O)=O)C(=O)CC1 OSINEUGRWRMBIN-UHFFFAOYSA-N 0.000 description 3
- GVQYJNATMYMBAT-UHFFFAOYSA-N 3,5-bis(4-fluorophenyl)-1h-pyrazole Chemical compound C1=CC(F)=CC=C1C1=NNC(C=2C=CC(F)=CC=2)=C1 GVQYJNATMYMBAT-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- NVYOYWJYOLJILH-UHFFFAOYSA-N 5-bromoazepan-4-one;hydrobromide Chemical compound Br.BrC1CCNCCC1=O NVYOYWJYOLJILH-UHFFFAOYSA-N 0.000 description 3
- RBDYQNIIWGTGOK-UHFFFAOYSA-N 5-methyl-2-piperidin-4-yl-1,3-oxazole Chemical compound O1C(C)=CN=C1C1CCNCC1 RBDYQNIIWGTGOK-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- WFTRLIZPJMFJER-UHFFFAOYSA-N azepan-1-ium-4-one;chloride Chemical compound Cl.O=C1CCCNCC1 WFTRLIZPJMFJER-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229940013688 formic acid Drugs 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 239000002469 receptor inverse agonist Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- BMLHPGOMLGKYIJ-UHFFFAOYSA-N tert-butyl 2-amino-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1SC(N)=N2 BMLHPGOMLGKYIJ-UHFFFAOYSA-N 0.000 description 3
- GWVKOWZXZDTZRL-UHFFFAOYSA-N tert-butyl 3-phenyl-5,6,8,9-tetrahydropyridazino[3,4-d]azepine-7-carboxylate Chemical compound N=1N=C2CCN(C(=O)OC(C)(C)C)CCC2=CC=1C1=CC=CC=C1 GWVKOWZXZDTZRL-UHFFFAOYSA-N 0.000 description 3
- SUGNMKNZPHTIFH-UHFFFAOYSA-N tert-butyl 4-(hydrazinecarbonyl)-4-methylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C)(C(=O)NN)CC1 SUGNMKNZPHTIFH-UHFFFAOYSA-N 0.000 description 3
- WFZYMTAEBJZITO-UHFFFAOYSA-N tert-butyl 4-methyl-4-(5-propan-2-yl-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate Chemical compound O1C(C(C)C)=NN=C1C1(C)CCN(C(=O)OC(C)(C)C)CC1 WFZYMTAEBJZITO-UHFFFAOYSA-N 0.000 description 3
- GLJYPTWEXBUATJ-UHFFFAOYSA-N tert-butyl 5-oxo-1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)CC1 GLJYPTWEXBUATJ-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- CGVVZBNOUVVSIJ-UHFFFAOYSA-N (1-benzyl-5-chloro-2,3,6,7-tetrahydroazepin-4-yl)-phenylmethanol Chemical compound ClC=1CCN(CC=2C=CC=CC=2)CCC=1C(O)C1=CC=CC=C1 CGVVZBNOUVVSIJ-UHFFFAOYSA-N 0.000 description 2
- LLQKDUDOHMJNDL-UHFFFAOYSA-N (1-benzyl-5-chloro-2,3,6,7-tetrahydroazepin-4-yl)-phenylmethanone Chemical compound C1CC(Cl)=C(C(=O)C=2C=CC=CC=2)CCN1CC1=CC=CC=C1 LLQKDUDOHMJNDL-UHFFFAOYSA-N 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MELFLZHZMUVTSQ-UHFFFAOYSA-N 1-(2-amino-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)-2-[3,5-bis(4-fluorophenyl)pyrazol-1-yl]ethanone Chemical compound C1CC=2SC(N)=NC=2CCN1C(=O)CN1N=C(C=2C=CC(F)=CC=2)C=C1C1=CC=C(F)C=C1 MELFLZHZMUVTSQ-UHFFFAOYSA-N 0.000 description 2
- TVYNCKITNNJYJU-UHFFFAOYSA-N 1-[4-(5-chloropyrimidin-2-yl)piperidin-1-yl]-2-(3,5-diphenylpyrazol-1-yl)ethanone Chemical compound N1=CC(Cl)=CN=C1C1CCN(C(=O)CN2C(=CC(=N2)C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 TVYNCKITNNJYJU-UHFFFAOYSA-N 0.000 description 2
- LRFHKHHUKGZIGE-UHFFFAOYSA-N 1-benzyl-2,5-dihydropyrrole Chemical compound C=1C=CC=CC=1CN1CC=CC1 LRFHKHHUKGZIGE-UHFFFAOYSA-N 0.000 description 2
- CDLXBQIIASVBAU-UHFFFAOYSA-N 1-benzyl-5-bromoazepan-4-one Chemical compound C1CC(=O)C(Br)CCN1CC1=CC=CC=C1 CDLXBQIIASVBAU-UHFFFAOYSA-N 0.000 description 2
- FXABBFMKFYNANI-UHFFFAOYSA-N 1-benzyl-5-chloro-2,3,6,7-tetrahydroazepine-4-carbaldehyde;hydrochloride Chemical compound Cl.C1CC(Cl)=C(C=O)CCN1CC1=CC=CC=C1 FXABBFMKFYNANI-UHFFFAOYSA-N 0.000 description 2
- RRVIUDRKTCAHQZ-UHFFFAOYSA-N 1-benzylazepan-4-one Chemical compound C1CC(=O)CCCN1CC1=CC=CC=C1 RRVIUDRKTCAHQZ-UHFFFAOYSA-N 0.000 description 2
- ZWZMANWVJJUNSZ-UHFFFAOYSA-N 1-chloroethyl 1h-azepine-3-carboxylate Chemical compound CC(Cl)OC(=O)C1=CNC=CC=C1 ZWZMANWVJJUNSZ-UHFFFAOYSA-N 0.000 description 2
- HHPOEUYEGWSEEL-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 4-(2-ethoxy-2-oxoethyl)-5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)CC1(C(=O)OCC)CCN(C(=O)OC(C)(C)C)CCC1=O HHPOEUYEGWSEEL-UHFFFAOYSA-N 0.000 description 2
- SNBGURLVYHVYEB-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 4-methylpiperidine-1,4-dicarboxylate Chemical compound COC(=O)C1(C)CCN(C(=O)OC(C)(C)C)CC1 SNBGURLVYHVYEB-UHFFFAOYSA-N 0.000 description 2
- NITOMRRFJBZOKI-UHFFFAOYSA-N 1-prop-2-enyl-3-(4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-yl)urea Chemical compound C1CNCC2=C1N=C(NC(=O)NCC=C)S2 NITOMRRFJBZOKI-UHFFFAOYSA-N 0.000 description 2
- GJPUTKWVQJEZPE-UHFFFAOYSA-N 1h-azepin-2-amine Chemical compound NC1=CC=CC=CN1 GJPUTKWVQJEZPE-UHFFFAOYSA-N 0.000 description 2
- PLSLNWUUAKBPFV-UHFFFAOYSA-N 2,7-dimethyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[4,5-d]azepine;dihydrobromide Chemical compound Br.Br.C1CNC(C)CC2=C1N=C(C)S2 PLSLNWUUAKBPFV-UHFFFAOYSA-N 0.000 description 2
- QZYBKQULJYQPKQ-UHFFFAOYSA-N 2-(1-benzyl-3,6-dihydro-2h-pyridin-4-yl)-5-methyl-1,3-oxazole Chemical compound O1C(C)=CN=C1C(CC1)=CCN1CC1=CC=CC=C1 QZYBKQULJYQPKQ-UHFFFAOYSA-N 0.000 description 2
- VRAWPSWNRQKESL-UHFFFAOYSA-N 2-(1-benzylpyridin-1-ium-4-yl)-5-methyl-1,3-oxazole Chemical compound O1C(C)=CN=C1C(C=C1)=CC=[N+]1CC1=CC=CC=C1 VRAWPSWNRQKESL-UHFFFAOYSA-N 0.000 description 2
- IAEGHQWWTAPASZ-UHFFFAOYSA-N 2-(4-methylpiperidin-4-yl)-5-propan-2-yl-1,3,4-oxadiazole Chemical compound O1C(C(C)C)=NN=C1C1(C)CCNCC1 IAEGHQWWTAPASZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SPFBMGTUOWUHEL-UHFFFAOYSA-N 2-methyl-5,6,7,8-tetrahydro-4h-[1,3]oxazolo[4,5-d]azepine;hydrochloride Chemical compound Cl.C1CNCCC2=C1N=C(C)O2 SPFBMGTUOWUHEL-UHFFFAOYSA-N 0.000 description 2
- BZWJXQOMKYUNBG-UHFFFAOYSA-N 2-methyl-5,6-dihydro-4h-pyrrolo[3,4-d][1,3]oxazole;hydroiodide Chemical compound I.C1NCC2=C1N=C(C)O2 BZWJXQOMKYUNBG-UHFFFAOYSA-N 0.000 description 2
- ATKHYOSOFMPPAP-UHFFFAOYSA-N 2-methyl-6,7,8,9-tetrahydro-5h-pyridazino[3,4-d]azepin-3-one;hydrochloride Chemical compound Cl.C1CNCCC2=CC(=O)N(C)N=C21 ATKHYOSOFMPPAP-UHFFFAOYSA-N 0.000 description 2
- PMDHIMMPXRSDML-UHFFFAOYSA-N 2-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC=N1 PMDHIMMPXRSDML-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- MMBXPQFHWZXSON-UHFFFAOYSA-N 3-bromo-7-methylazepan-4-one;hydrobromide Chemical compound Br.CC1CCC(=O)C(Br)CN1 MMBXPQFHWZXSON-UHFFFAOYSA-N 0.000 description 2
- OEXCMWXGWPQSDP-UHFFFAOYSA-N 3-bromopiperidin-4-one;hydrobromide Chemical compound Br.BrC1CNCCC1=O OEXCMWXGWPQSDP-UHFFFAOYSA-N 0.000 description 2
- XKOPQQDVZXXTKQ-UHFFFAOYSA-N 3-methyl-6,7,8,9-tetrahydro-5h-imidazo[1,2-a][1,4]diazepine;dihydrochloride Chemical compound Cl.Cl.C1NCCCN2C(C)=CN=C21 XKOPQQDVZXXTKQ-UHFFFAOYSA-N 0.000 description 2
- OAVAAGOKFIYQGE-UHFFFAOYSA-N 3-oxo-5,6,8,9-tetrahydro-2H-pyridazino[3,4-d]azepine-7-carboxylic acid Chemical compound C1CN(C(=O)O)CCC2=CC(=O)NN=C21 OAVAAGOKFIYQGE-UHFFFAOYSA-N 0.000 description 2
- PPONBNYOLVQUCA-UHFFFAOYSA-N 3-phenyl-6,7,8,9-tetrahydro-5h-pyridazino[3,4-d]azepine;dihydrochloride Chemical compound Cl.Cl.N=1N=C2CCNCCC2=CC=1C1=CC=CC=C1 PPONBNYOLVQUCA-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- KLJGSQVYUGQOAW-UHFFFAOYSA-N 4-chloro-6-methoxypyrimidine Chemical compound COC1=CC(Cl)=NC=N1 KLJGSQVYUGQOAW-UHFFFAOYSA-N 0.000 description 2
- MZOIHGHGWXSLJH-UHFFFAOYSA-N 4-phenyl-6,7,8,9-tetrahydro-5h-pyrimido[4,5-d]azepine;hydrochloride Chemical compound Cl.C=12CCNCCC2=NC=NC=1C1=CC=CC=C1 MZOIHGHGWXSLJH-UHFFFAOYSA-N 0.000 description 2
- UJTOOQQNMGNOTD-UHFFFAOYSA-N 5-bromo-7-methylazepan-4-one;hydrobromide Chemical compound Br.CC1CC(Br)C(=O)CCN1 UJTOOQQNMGNOTD-UHFFFAOYSA-N 0.000 description 2
- XKJUVROKPQBNPR-UHFFFAOYSA-N 5-methyl-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-oxazole;hydrochloride Chemical compound Cl.O1C(C)=CN=C1C1=CCNCC1 XKJUVROKPQBNPR-UHFFFAOYSA-N 0.000 description 2
- KUOKMUKOOXRLQJ-UHFFFAOYSA-N 5-methyl-3-piperazin-1-yl-1,2,4-oxadiazole;hydrochloride Chemical compound Cl.O1C(C)=NC(N2CCNCC2)=N1 KUOKMUKOOXRLQJ-UHFFFAOYSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- NPWOSQRRCSBZSK-UHFFFAOYSA-N 7-benzyl-4-phenyl-5,6,8,9-tetrahydropyrimido[4,5-d]azepine Chemical compound C=1C=CC=CC=1CN(CCC1=2)CCC1=NC=NC=2C1=CC=CC=C1 NPWOSQRRCSBZSK-UHFFFAOYSA-N 0.000 description 2
- ZJVVGMWRINDWHN-UHFFFAOYSA-N 7-benzyl-n-phenyl-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-2-amine Chemical compound C=1C=CC=CC=1CN(CCC1=N2)CCC1=CN=C2NC1=CC=CC=C1 ZJVVGMWRINDWHN-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RPZIGEBYAZIRQS-UHFFFAOYSA-N Cc1nc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c(cc2)cc(C)c2F)=O)n[o]1 Chemical compound Cc1nc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c(cc2)cc(C)c2F)=O)n[o]1 RPZIGEBYAZIRQS-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000027484 GABAA receptors Human genes 0.000 description 2
- 108091008681 GABAA receptors Proteins 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000007216 Muscarinic M4 Receptor Human genes 0.000 description 2
- 108010008414 Muscarinic M4 Receptor Proteins 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GNRFEHXMWFHVBQ-UHFFFAOYSA-N benzyl 2,3,6,7-tetrahydroazepine-1-carboxylate Chemical compound C1CC=CCCN1C(=O)OCC1=CC=CC=C1 GNRFEHXMWFHVBQ-UHFFFAOYSA-N 0.000 description 2
- ZBJWNMAOUWMLOH-UHFFFAOYSA-N benzyl 2-methyl-4,5,7,8-tetrahydro-[1,3]oxazolo[4,5-d]azepine-6-carboxylate Chemical compound C1CC=2OC(C)=NC=2CCN1C(=O)OCC1=CC=CC=C1 ZBJWNMAOUWMLOH-UHFFFAOYSA-N 0.000 description 2
- JHQSFHXMUXUVBC-UHFFFAOYSA-N benzyl 2-methyl-4,6-dihydropyrrolo[3,4-d][1,3]oxazole-5-carboxylate Chemical compound C1C=2OC(C)=NC=2CN1C(=O)OCC1=CC=CC=C1 JHQSFHXMUXUVBC-UHFFFAOYSA-N 0.000 description 2
- SBSFLCICDRKZNZ-UHFFFAOYSA-N benzyl 3-acetamido-4-hydroxypyrrolidine-1-carboxylate Chemical compound C1C(O)C(NC(=O)C)CN1C(=O)OCC1=CC=CC=C1 SBSFLCICDRKZNZ-UHFFFAOYSA-N 0.000 description 2
- CYAUWJFQAOIMDM-UHFFFAOYSA-N benzyl 3-acetamido-4-oxopyrrolidine-1-carboxylate Chemical compound C1C(=O)C(NC(=O)C)CN1C(=O)OCC1=CC=CC=C1 CYAUWJFQAOIMDM-UHFFFAOYSA-N 0.000 description 2
- IXPLJRREJIUKLG-UHFFFAOYSA-N benzyl 3-amino-4-hydroxypyrrolidine-1-carboxylate Chemical compound C1C(O)C(N)CN1C(=O)OCC1=CC=CC=C1 IXPLJRREJIUKLG-UHFFFAOYSA-N 0.000 description 2
- MWLRYCCPMAPQMW-UHFFFAOYSA-N benzyl 4-acetamido-5-hydroxyazepane-1-carboxylate Chemical compound C1CC(O)C(NC(=O)C)CCN1C(=O)OCC1=CC=CC=C1 MWLRYCCPMAPQMW-UHFFFAOYSA-N 0.000 description 2
- UFGAURSFRBLZAA-UHFFFAOYSA-N benzyl 4-acetamido-5-oxoazepane-1-carboxylate Chemical compound C1CC(=O)C(NC(=O)C)CCN1C(=O)OCC1=CC=CC=C1 UFGAURSFRBLZAA-UHFFFAOYSA-N 0.000 description 2
- FZDACFZWWMAUBO-UHFFFAOYSA-N benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1C2OC2CN1C(=O)OCC1=CC=CC=C1 FZDACFZWWMAUBO-UHFFFAOYSA-N 0.000 description 2
- IITJMAOVBYABLN-UHFFFAOYSA-N benzyl 8-oxa-4-azabicyclo[5.1.0]octane-4-carboxylate Chemical compound C1CC2OC2CCN1C(=O)OCC1=CC=CC=C1 IITJMAOVBYABLN-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- CJZBGQVBZYTGLS-UHFFFAOYSA-N benzyl n,n-bis(but-3-enyl)carbamate Chemical compound C=CCCN(CCC=C)C(=O)OCC1=CC=CC=C1 CJZBGQVBZYTGLS-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940042053 methotrimeprazine Drugs 0.000 description 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- WJUHYXHQRFJCBI-UHFFFAOYSA-N methyl 2-pyrazol-1-ylacetate Chemical compound COC(=O)CN1C=CC=N1 WJUHYXHQRFJCBI-UHFFFAOYSA-N 0.000 description 2
- CJWQMQIEJQPIKF-UHFFFAOYSA-N methyl 5-fluoro-4-methylpyridine-2-carboxylate Chemical compound COC(=O)C1=CC(C)=C(F)C=N1 CJWQMQIEJQPIKF-UHFFFAOYSA-N 0.000 description 2
- VJQANAFOOBEGMM-UHFFFAOYSA-N n-(2,3,4,5-tetrahydro-1h-3-benzazepin-7-yl)acetamide Chemical compound C1CNCCC2=CC(NC(=O)C)=CC=C21 VJQANAFOOBEGMM-UHFFFAOYSA-N 0.000 description 2
- AQXRBEHWQCOKJI-UHFFFAOYSA-N n-(2-hydroxypropyl)pyridine-4-carboxamide Chemical compound CC(O)CNC(=O)C1=CC=NC=C1 AQXRBEHWQCOKJI-UHFFFAOYSA-N 0.000 description 2
- GQUOIJGGDBURRP-UHFFFAOYSA-N n-(2-oxopropyl)pyridine-4-carboxamide Chemical compound CC(=O)CNC(=O)C1=CC=NC=C1 GQUOIJGGDBURRP-UHFFFAOYSA-N 0.000 description 2
- LCRCELDHELADLD-UHFFFAOYSA-N n-[3-(2,2,2-trifluoroacetyl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]acetamide Chemical compound C1CN(C(=O)C(F)(F)F)CCC2=CC(NC(=O)C)=CC=C21 LCRCELDHELADLD-UHFFFAOYSA-N 0.000 description 2
- XLFNQQVWGHEPGW-UHFFFAOYSA-N n-benzyl-n-but-3-enylbut-3-en-1-amine Chemical compound C=CCCN(CCC=C)CC1=CC=CC=C1 XLFNQQVWGHEPGW-UHFFFAOYSA-N 0.000 description 2
- BQTJJVBQSIIAAA-UHFFFAOYSA-N n-phenyl-6,7,8,9-tetrahydro-5h-pyrimido[4,5-d]azepin-2-amine Chemical compound N1=C2CCNCCC2=CN=C1NC1=CC=CC=C1 BQTJJVBQSIIAAA-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960004431 quetiapine Drugs 0.000 description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- YKGPLWXFHXJVLP-UHFFFAOYSA-N tert-butyl 2,7-dimethyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepine-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)C(C)CC2=C1N=C(C)S2 YKGPLWXFHXJVLP-UHFFFAOYSA-N 0.000 description 2
- RWCRNTVXTCSPPE-UHFFFAOYSA-N tert-butyl 2-(phenoxycarbonylamino)-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound S1C=2CN(C(=O)OC(C)(C)C)CCC=2N=C1NC(=O)OC1=CC=CC=C1 RWCRNTVXTCSPPE-UHFFFAOYSA-N 0.000 description 2
- BZVHNQVHNOYNKI-UHFFFAOYSA-N tert-butyl 2-(prop-2-enylcarbamoylamino)-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1SC(NC(=O)NCC=C)=N2 BZVHNQVHNOYNKI-UHFFFAOYSA-N 0.000 description 2
- CIEFBAXZZCPNLH-UHFFFAOYSA-N tert-butyl 2-amino-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepine-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=C1SC(N)=N2 CIEFBAXZZCPNLH-UHFFFAOYSA-N 0.000 description 2
- GVOXIQKNXSYOQY-UHFFFAOYSA-N tert-butyl 2-methyl-3-oxo-4,4a,5,6,8,9-hexahydropyridazino[3,4-d]azepine-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2CC(=O)N(C)N=C21 GVOXIQKNXSYOQY-UHFFFAOYSA-N 0.000 description 2
- UGZDPIHZKIAAQR-UHFFFAOYSA-N tert-butyl 3-chloro-5,6,8,9-tetrahydropyridazino[3,4-d]azepine-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=CC(Cl)=NN=C21 UGZDPIHZKIAAQR-UHFFFAOYSA-N 0.000 description 2
- GBUUKYCTEQVLKG-UHFFFAOYSA-N tert-butyl 3-methyl-6,7,8,9-tetrahydro-5h-imidazo[1,2-a][1,4]diazepine-7-carboxylate Chemical compound C1NC(C(=O)OC(C)(C)C)CCN2C(C)=CN=C21 GBUUKYCTEQVLKG-UHFFFAOYSA-N 0.000 description 2
- VEJQBBTYVPNMNJ-UHFFFAOYSA-N tert-butyl 3-oxo-4,4a,5,6,8,9-hexahydro-2h-pyridazino[3,4-d]azepine-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2CC(=O)NN=C21 VEJQBBTYVPNMNJ-UHFFFAOYSA-N 0.000 description 2
- FDZFRHHKHQEPKL-UHFFFAOYSA-N tert-butyl 4-(5-methyl-1,2,4-oxadiazol-3-yl)piperazine-1-carboxylate Chemical compound O1C(C)=NC(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 FDZFRHHKHQEPKL-UHFFFAOYSA-N 0.000 description 2
- MVVKOARUELORGT-UHFFFAOYSA-N tert-butyl 4-(6-methoxypyrimidin-4-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1=NC(OC)=CC(C=2CCN(CC=2)C(=O)OC(C)(C)C)=N1 MVVKOARUELORGT-UHFFFAOYSA-N 0.000 description 2
- QKPZLLSIRXTNTG-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-pyrimidin-2-ylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C1=NC=CC=N1 QKPZLLSIRXTNTG-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical compound CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- OKHUDYOUNFDWEI-BGERDNNASA-N (2s)-2-amino-1-(2-diphenoxyphosphorylpyrrolidin-1-yl)-3-(1h-imidazol-5-yl)propan-1-one Chemical compound C([C@H](N)C(=O)N1C(CCC1)P(=O)(OC=1C=CC=CC=1)OC=1C=CC=CC=1)C1=CN=CN1 OKHUDYOUNFDWEI-BGERDNNASA-N 0.000 description 1
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BGLARIMANCDMQX-UHFFFAOYSA-N 1,1,1-trimethoxy-2-methylpropane Chemical compound COC(OC)(OC)C(C)C BGLARIMANCDMQX-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical class Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 1
- MAFMDAMXSHBOOZ-UHFFFAOYSA-N 1-(7-amino-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CCC2=CC(N)=CC=C21 MAFMDAMXSHBOOZ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- MLBHFBKZUPLWBD-UHFFFAOYSA-N 1-[3-(trifluoromethyl)phenyl]-2-propanamine Chemical compound CC(N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- TVUIYWDZNFGFTC-UHFFFAOYSA-N 1-benzyl-5-chloro-2,3,6,7-tetrahydroazepine-4-carbaldehyde Chemical compound C1CC(Cl)=C(C=O)CCN1CC1=CC=CC=C1 TVUIYWDZNFGFTC-UHFFFAOYSA-N 0.000 description 1
- TVIICJDDSIMWQT-UHFFFAOYSA-N 1-benzylazepan-4-one;hydrochloride Chemical compound Cl.C1CC(=O)CCCN1CC1=CC=CC=C1 TVIICJDDSIMWQT-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- PTZNCCIULVXFIJ-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 PTZNCCIULVXFIJ-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- GNLQYCPHDQMWBW-UHFFFAOYSA-N 11-methyl-2,3,4,5-tetrahydro-1h-azepino[4,5-b]quinoline Chemical compound C1CNCCC2=NC3=CC=CC=C3C(C)=C21 GNLQYCPHDQMWBW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GLOHJSJBTWQDOB-UHFFFAOYSA-N 2,6-dimethyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-c]azepine;2,7-dimethyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[4,5-d]azepine;dihydrobromide Chemical compound Br.Br.C1NC(C)CCC2=C1SC(C)=N2.C1CNC(C)CC2=C1N=C(C)S2 GLOHJSJBTWQDOB-UHFFFAOYSA-N 0.000 description 1
- DVYPPYDPABRCFR-UHFFFAOYSA-N 2,6-dimethyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-c]azepine;hydrobromide Chemical compound Br.C1NC(C)CCC2=C1SC(C)=N2 DVYPPYDPABRCFR-UHFFFAOYSA-N 0.000 description 1
- CPXUSQZOGFOYEH-UHFFFAOYSA-N 2,7-dimethyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[4,5-d]azepine;hydrobromide Chemical compound Br.C1CNC(C)CC2=C1N=C(C)S2 CPXUSQZOGFOYEH-UHFFFAOYSA-N 0.000 description 1
- GMACPPQKLRQSSU-UHFFFAOYSA-N 2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.OCCNCCO GMACPPQKLRQSSU-UHFFFAOYSA-N 0.000 description 1
- IIHJYPFNYZEWPS-UHFFFAOYSA-N 2-(3,5-diphenylpyrazol-1-yl)acetic acid Chemical compound OC(=O)CN1N=C(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 IIHJYPFNYZEWPS-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- VSGSHSBVOMHSHJ-UHFFFAOYSA-N 2-[3,5-bis(4-fluorophenyl)pyrazol-1-yl]acetic acid Chemical compound OC(=O)CN1N=C(C=2C=CC(F)=CC=2)C=C1C1=CC=C(F)C=C1 VSGSHSBVOMHSHJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BBFCZCZRPXGONA-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO BBFCZCZRPXGONA-UHFFFAOYSA-N 0.000 description 1
- WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- DUGMCDWNXXFHDE-VZYDHVRKSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 DUGMCDWNXXFHDE-VZYDHVRKSA-N 0.000 description 1
- CYXOICAPNITIOW-UHFFFAOYSA-N 2-bromo-5-fluoro-4-methylpyridine Chemical compound CC1=CC(Br)=NC=C1F CYXOICAPNITIOW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BKUIZWILNWHFHD-UHFFFAOYSA-N 3-cyano-n-(2,5-diphenylpyrazol-3-yl)benzamide Chemical compound C=1C=CC(C#N)=CC=1C(=O)NC1=CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 BKUIZWILNWHFHD-UHFFFAOYSA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- YYZRTZLOUDOIGR-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine Chemical compound C1CNCC2=C1N=C(N)S2 YYZRTZLOUDOIGR-UHFFFAOYSA-N 0.000 description 1
- WSYOBFPJSWHLHC-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine;dihydrobromide Chemical compound Br.Br.C1CNCC2=C1N=C(N)S2 WSYOBFPJSWHLHC-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
- CDXPHWPBCCAEPW-UHFFFAOYSA-N 4-methoxy-6-piperidin-4-ylpyrimidine Chemical compound C1=NC(OC)=CC(C2CCNCC2)=N1 CDXPHWPBCCAEPW-UHFFFAOYSA-N 0.000 description 1
- XMFNEUZYMYOUAH-UHFFFAOYSA-N 4-methyl-2-piperazin-1-yl-1,3-oxazole;hydrochloride Chemical compound Cl.CC1=COC(N2CCNCC2)=N1 XMFNEUZYMYOUAH-UHFFFAOYSA-N 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- WLURPUFWHRATRI-UHFFFAOYSA-N 5,6,7,8-tetrahydro-4h-[1,3]oxazolo[4,5-d]azepin-2-amine Chemical compound C1CNCCC2=C1N=C(N)O2 WLURPUFWHRATRI-UHFFFAOYSA-N 0.000 description 1
- QEFFZWNEMCFCAN-UHFFFAOYSA-N 5,6-dimethylpyridine-2-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)N=C1C QEFFZWNEMCFCAN-UHFFFAOYSA-N 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- 108091005435 5-HT6 receptors Proteins 0.000 description 1
- MZFILKOHQHVLSO-UHFFFAOYSA-N 5-chloro-2-piperidin-4-ylpyrimidine Chemical compound N1=CC(Cl)=CN=C1C1CCNCC1 MZFILKOHQHVLSO-UHFFFAOYSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- YEDBPZLLQNEEKB-UHFFFAOYSA-N 7-methylazepan-4-one;hydrobromide Chemical compound Br.CC1CCC(=O)CCN1 YEDBPZLLQNEEKB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 239000000774 AMPA receptor agonist Substances 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- SNGYKXVYVJPHGY-UHFFFAOYSA-N CC(C(C=C1)F)C=C1c1n[n](CC(C2CC2)N(C2)Cc3c2nc(C)[o]3)c(C)c1 Chemical compound CC(C(C=C1)F)C=C1c1n[n](CC(C2CC2)N(C2)Cc3c2nc(C)[o]3)c(C)c1 SNGYKXVYVJPHGY-UHFFFAOYSA-N 0.000 description 1
- RHDUIDACUBLLNZ-UHFFFAOYSA-N CC(C)c1cc(-c(cc2)cc(C)c2F)n[n]1CC(N(CC1)CCc2c1nc(N)[s]2)=O Chemical compound CC(C)c1cc(-c(cc2)cc(C)c2F)n[n]1CC(N(CC1)CCc2c1nc(N)[s]2)=O RHDUIDACUBLLNZ-UHFFFAOYSA-N 0.000 description 1
- SJWUKLCGTWWAEK-UHFFFAOYSA-N CC(C)c1cc(-c(cc2)ccc2F)c[n]1CC(OC)=O Chemical compound CC(C)c1cc(-c(cc2)ccc2F)c[n]1CC(OC)=O SJWUKLCGTWWAEK-UHFFFAOYSA-N 0.000 description 1
- ZXSFSOPQZMCMJN-UHFFFAOYSA-N CC(CC1)OC(C2)=C1CCN2N Chemical compound CC(CC1)OC(C2)=C1CCN2N ZXSFSOPQZMCMJN-UHFFFAOYSA-N 0.000 description 1
- GVIQOOGCLJWZJI-UHFFFAOYSA-N CC(C[n](c(C)c1)nc1-c1cc(C)ccc1)N(CC1)CCC1C(CC=C1)=NC=C1OC Chemical compound CC(C[n](c(C)c1)nc1-c1cc(C)ccc1)N(CC1)CCC1C(CC=C1)=NC=C1OC GVIQOOGCLJWZJI-UHFFFAOYSA-N 0.000 description 1
- OSWATDCZZQKAAL-UHFFFAOYSA-N CC(NC(C1)C=CC2=C1CCNCC2)=O Chemical compound CC(NC(C1)C=CC2=C1CCNCC2)=O OSWATDCZZQKAAL-UHFFFAOYSA-N 0.000 description 1
- QUKGYYKBILRGFE-UHFFFAOYSA-N CC(OCc1ccccc1)=O Chemical compound CC(OCc1ccccc1)=O QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 1
- VAQYWSWKLMDPBK-UHFFFAOYSA-N CC1=C(C)SC(CN(C)CC2)=C2C1 Chemical compound CC1=C(C)SC(CN(C)CC2)=C2C1 VAQYWSWKLMDPBK-UHFFFAOYSA-N 0.000 description 1
- JFFXMRIGSXCSQS-UHFFFAOYSA-N CC1=C(N)SC(C[NH+](CC2)[NH-])=C2CC1 Chemical compound CC1=C(N)SC(C[NH+](CC2)[NH-])=C2CC1 JFFXMRIGSXCSQS-UHFFFAOYSA-N 0.000 description 1
- FTBIXUDNWDUNKT-UHFFFAOYSA-N CC1C(CC(OCc2ccccc2)=O)C(C)CC(CN)C1 Chemical compound CC1C(CC(OCc2ccccc2)=O)C(C)CC(CN)C1 FTBIXUDNWDUNKT-UHFFFAOYSA-N 0.000 description 1
- WEWUDLJJHPTQCQ-UHFFFAOYSA-N CCC(CC(c(cc1C)ccc1N)=O)=O Chemical compound CCC(CC(c(cc1C)ccc1N)=O)=O WEWUDLJJHPTQCQ-UHFFFAOYSA-N 0.000 description 1
- WIYPLPZEPWZEKF-UHFFFAOYSA-N CCC(CC(c1cc(C#N)ccc1)=O)=O Chemical compound CCC(CC(c1cc(C#N)ccc1)=O)=O WIYPLPZEPWZEKF-UHFFFAOYSA-N 0.000 description 1
- MSWFSVFSPAESJF-DNMBWQPZSA-N CCC/C(/C)=C/C(/c(cc1)nc(C)c1F)=N\NCC(N(C1)Cc2c1nc(C)[o]2)=O Chemical compound CCC/C(/C)=C/C(/c(cc1)nc(C)c1F)=N\NCC(N(C1)Cc2c1nc(C)[o]2)=O MSWFSVFSPAESJF-DNMBWQPZSA-N 0.000 description 1
- DJPCUFUYOBCADG-UHFFFAOYSA-N CCC1=CC(c2cc(Cl)ccc2)=NCC1CC(O)=O Chemical compound CCC1=CC(c2cc(Cl)ccc2)=NCC1CC(O)=O DJPCUFUYOBCADG-UHFFFAOYSA-N 0.000 description 1
- BCSMYRVOEQEOSV-UHFFFAOYSA-N CCCC1=CC(c(cc2C)ccc2F)=CCN1CC(O)=O Chemical compound CCCC1=CC(c(cc2C)ccc2F)=CCN1CC(O)=O BCSMYRVOEQEOSV-UHFFFAOYSA-N 0.000 description 1
- BBKOEWDCEVZDSQ-UHFFFAOYSA-N CCCc1cc(-c(cc2C)ccc2F)n[n]1CC(N(CC1)CCN1c1nc(C)c[o]1)=O Chemical compound CCCc1cc(-c(cc2C)ccc2F)n[n]1CC(N(CC1)CCN1c1nc(C)c[o]1)=O BBKOEWDCEVZDSQ-UHFFFAOYSA-N 0.000 description 1
- ADXPOEFCJJBVNR-UHFFFAOYSA-N CCCc1cc(-c(cc2C)ccc2F)n[n]1CC(OC)=O Chemical compound CCCc1cc(-c(cc2C)ccc2F)n[n]1CC(OC)=O ADXPOEFCJJBVNR-UHFFFAOYSA-N 0.000 description 1
- PVQSUMWQJORZHI-UHFFFAOYSA-N CCc1cc(-c(cc2C)ccc2F)n[n]1CC(N(CC1)CCC1c1nnc(CC)[o]1)=O Chemical compound CCc1cc(-c(cc2C)ccc2F)n[n]1CC(N(CC1)CCC1c1nnc(CC)[o]1)=O PVQSUMWQJORZHI-UHFFFAOYSA-N 0.000 description 1
- ICBKTKTZMNVGTN-UHFFFAOYSA-N CCc1cc(-c(cc2C)ccc2F)n[n]1CC(N(CC1)CCN1c1nnc(CC)[o]1)=O Chemical compound CCc1cc(-c(cc2C)ccc2F)n[n]1CC(N(CC1)CCN1c1nnc(CC)[o]1)=O ICBKTKTZMNVGTN-UHFFFAOYSA-N 0.000 description 1
- LCQVWTOHGGWQKH-UHFFFAOYSA-N CCc1cc(-c(cc2C)ccc2F)n[n]1CC(N1Cc2ncccc2C1)=O Chemical compound CCc1cc(-c(cc2C)ccc2F)n[n]1CC(N1Cc2ncccc2C1)=O LCQVWTOHGGWQKH-UHFFFAOYSA-N 0.000 description 1
- DJJOCHSIKWEPQC-UHFFFAOYSA-N CCc1cc(-c2cc(C#N)ccc2)n[nH]1 Chemical compound CCc1cc(-c2cc(C#N)ccc2)n[nH]1 DJJOCHSIKWEPQC-UHFFFAOYSA-N 0.000 description 1
- PTEBXZWEGUVFDT-UHFFFAOYSA-N CCc1cc(-c2cc(C#N)ccc2)n[n]1CC(N(CC1)CCN1c1nnc(C)[o]1)=O Chemical compound CCc1cc(-c2cc(C#N)ccc2)n[n]1CC(N(CC1)CCN1c1nnc(C)[o]1)=O PTEBXZWEGUVFDT-UHFFFAOYSA-N 0.000 description 1
- RGJRCHWOCMSFSA-UHFFFAOYSA-N CCc1cc(-c2cc(C)ccc2)n[n]1CC(N(CC1)CCc2c1nc(N)[s]2)=O Chemical compound CCc1cc(-c2cc(C)ccc2)n[n]1CC(N(CC1)CCc2c1nc(N)[s]2)=O RGJRCHWOCMSFSA-UHFFFAOYSA-N 0.000 description 1
- CYSCLTYBWLSUCH-UHFFFAOYSA-N CCc1cc(-c2cc(Cl)ccc2)n[nH]1 Chemical compound CCc1cc(-c2cc(Cl)ccc2)n[nH]1 CYSCLTYBWLSUCH-UHFFFAOYSA-N 0.000 description 1
- QQUGUVFEWYRRLJ-UHFFFAOYSA-N CCc1cc(-c2ccc(C)c(F)c2)n[n]1CC(N(C1)Cc2c1nc(C)[s]2)=O Chemical compound CCc1cc(-c2ccc(C)c(F)c2)n[n]1CC(N(C1)Cc2c1nc(C)[s]2)=O QQUGUVFEWYRRLJ-UHFFFAOYSA-N 0.000 description 1
- LVSNZNBGAFVVEV-UHFFFAOYSA-N CCc1cc(-c2ccc(C)c(F)c2)n[n]1CC(O)=O Chemical compound CCc1cc(-c2ccc(C)c(F)c2)n[n]1CC(O)=O LVSNZNBGAFVVEV-UHFFFAOYSA-N 0.000 description 1
- GJUWLGVFUTYSHC-UHFFFAOYSA-N CCc1cccc(C2=[I][IH]N(CC(N(CC3)CCc4c3nc(C)[s]4)=O)C(CC)=C2)c1 Chemical compound CCc1cccc(C2=[I][IH]N(CC(N(CC3)CCc4c3nc(C)[s]4)=O)C(CC)=C2)c1 GJUWLGVFUTYSHC-UHFFFAOYSA-N 0.000 description 1
- NMNYUGBHCGQGJW-UHFFFAOYSA-N CN(CC1)Cc2c1nc(NC(NCC=C)=O)[s]2 Chemical compound CN(CC1)Cc2c1nc(NC(NCC=C)=O)[s]2 NMNYUGBHCGQGJW-UHFFFAOYSA-N 0.000 description 1
- LJQKABNFBNVUOX-UHFFFAOYSA-N CNc1ccc(CCN(C2)N)c2c1 Chemical compound CNc1ccc(CCN(C2)N)c2c1 LJQKABNFBNVUOX-UHFFFAOYSA-N 0.000 description 1
- NJJVQAFYMVKKSR-UHFFFAOYSA-N COC(c1ccc(CN(CC2)N)c2c1)=O Chemical compound COC(c1ccc(CN(CC2)N)c2c1)=O NJJVQAFYMVKKSR-UHFFFAOYSA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- LXQCCUOYCCQBIX-SDNWHVSQSA-N COc(cc(cc1)C(/C=C(\CCC(O)=O)/c2ccccc2)=[N-])c1F Chemical compound COc(cc(cc1)C(/C=C(\CCC(O)=O)/c2ccccc2)=[N-])c1F LXQCCUOYCCQBIX-SDNWHVSQSA-N 0.000 description 1
- FLMXGSAEXWPMQO-UHFFFAOYSA-N COc1cccc(C2)c1CCN2N Chemical compound COc1cccc(C2)c1CCN2N FLMXGSAEXWPMQO-UHFFFAOYSA-N 0.000 description 1
- CEVWCTWEPACIJS-UHFFFAOYSA-N COc1nc(CCC(Cc2ccccc2)CC2)c2[s]1 Chemical compound COc1nc(CCC(Cc2ccccc2)CC2)c2[s]1 CEVWCTWEPACIJS-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- NJXVTZVHAKOZKL-UHFFFAOYSA-N Cc(cc1)cnc1C1=CCN(CC(OC)=O)C(c2ccccc2)=C1 Chemical compound Cc(cc1)cnc1C1=CCN(CC(OC)=O)C(c2ccccc2)=C1 NJXVTZVHAKOZKL-UHFFFAOYSA-N 0.000 description 1
- CKUBKXYMTNUIOI-UHFFFAOYSA-N Cc1cc(-c2n[n](CC(N(CC3)CCc4c3cc[s]4)=O)c(-c3ccccc3)c2)ccc1F Chemical compound Cc1cc(-c2n[n](CC(N(CC3)CCc4c3cc[s]4)=O)c(-c3ccccc3)c2)ccc1F CKUBKXYMTNUIOI-UHFFFAOYSA-N 0.000 description 1
- HYCICHUTLUEBAL-UHFFFAOYSA-N Cc1cc(C2=CCN(C3C(N(CC4)CC=C4c4cc(OC)ncn4)OC3)C(c3ccccc3)=C2)ccc1F Chemical compound Cc1cc(C2=CCN(C3C(N(CC4)CC=C4c4cc(OC)ncn4)OC3)C(c3ccccc3)=C2)ccc1F HYCICHUTLUEBAL-UHFFFAOYSA-N 0.000 description 1
- VPZCYVCHFLRUMQ-UHFFFAOYSA-N Cc1ccc(-c2n[n](CC(N(CC3)CCc4c3nc(N)[s]4)=O)c(-c3ccccc3)c2)nc1C Chemical compound Cc1ccc(-c2n[n](CC(N(CC3)CCc4c3nc(N)[s]4)=O)c(-c3ccccc3)c2)nc1C VPZCYVCHFLRUMQ-UHFFFAOYSA-N 0.000 description 1
- PNPWBJFPQOXZKX-UHFFFAOYSA-N Cc1cccc(-c2n[n](CC(N(CC3)CCc4c3nc(N)[s]4)=O)c(-c3ccccc3)c2)c1 Chemical compound Cc1cccc(-c2n[n](CC(N(CC3)CCc4c3nc(N)[s]4)=O)c(-c3ccccc3)c2)c1 PNPWBJFPQOXZKX-UHFFFAOYSA-N 0.000 description 1
- PQRRFZJJDXXPLB-UHFFFAOYSA-N Cc1cnc(C(CC2)=CCN2C(C[n](c(-c2ccccc2)c2)nc2-c2cc(C#N)ccc2)=O)[o]1 Chemical compound Cc1cnc(C(CC2)=CCN2C(C[n](c(-c2ccccc2)c2)nc2-c2cc(C#N)ccc2)=O)[o]1 PQRRFZJJDXXPLB-UHFFFAOYSA-N 0.000 description 1
- BWDLLJHNGNMJLW-UHFFFAOYSA-N Cc1cnc(C(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c2cc(C#N)ccc2)=O)[o]1 Chemical compound Cc1cnc(C(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c2cc(C#N)ccc2)=O)[o]1 BWDLLJHNGNMJLW-UHFFFAOYSA-N 0.000 description 1
- BIIYISMZPZZISJ-UHFFFAOYSA-N Cc1n[n](CCN(CC2)C(C[n](c(-c3ccccc3)c3)nc3-c(cc3C)ccc3F)=O)c2n1 Chemical compound Cc1n[n](CCN(CC2)C(C[n](c(-c3ccccc3)c3)nc3-c(cc3C)ccc3F)=O)c2n1 BIIYISMZPZZISJ-UHFFFAOYSA-N 0.000 description 1
- JHATYWPKPMGKAW-UHFFFAOYSA-N Cc1nc(CCCCC2)c2[s]1 Chemical compound Cc1nc(CCCCC2)c2[s]1 JHATYWPKPMGKAW-UHFFFAOYSA-N 0.000 description 1
- XOVNRSQXLWCNPJ-UHFFFAOYSA-N Cc1nc(CCN(CC2)C(C[n](c(-c3ccccc3)c3)nc3-c(cc3C)ccc3OC)=O)c2[s]1 Chemical compound Cc1nc(CCN(CC2)C(C[n](c(-c3ccccc3)c3)nc3-c(cc3C)ccc3OC)=O)c2[s]1 XOVNRSQXLWCNPJ-UHFFFAOYSA-N 0.000 description 1
- QZCDGRAPBBUCDE-UHFFFAOYSA-N Cc1nc(CCN(CC2)C(C[n](c(-c3ccccc3)c3)nc3-c3ccc(C(F)F)cc3)=O)c2[s]1 Chemical compound Cc1nc(CCN(CC2)C(C[n](c(-c3ccccc3)c3)nc3-c3ccc(C(F)F)cc3)=O)c2[s]1 QZCDGRAPBBUCDE-UHFFFAOYSA-N 0.000 description 1
- BZULUDPCJSLNKN-UHFFFAOYSA-N Cc1nc(CN(C2)C(CN(C(C3)c4ccccc4)N=C3c(cc3)cc(C)c3OC)=O)c2[s]1 Chemical compound Cc1nc(CN(C2)C(CN(C(C3)c4ccccc4)N=C3c(cc3)cc(C)c3OC)=O)c2[s]1 BZULUDPCJSLNKN-UHFFFAOYSA-N 0.000 description 1
- DMWOSOUDLKFJCQ-UHFFFAOYSA-N Cc1nc(CN(C2)C(C[n](c(-c(cc3)ccc3F)c3)nc3-c(nc3)ccc3F)=O)c2[s]1 Chemical compound Cc1nc(CN(C2)C(C[n](c(-c(cc3)ccc3F)c3)nc3-c(nc3)ccc3F)=O)c2[s]1 DMWOSOUDLKFJCQ-UHFFFAOYSA-N 0.000 description 1
- MBGYVBWDLLCVIS-UHFFFAOYSA-N Cc1nc(CN(C2)C(C[n](c(-c3ccccc3)c3)nc3-c(cc3)ccc3OC(F)F)=O)c2[o]1 Chemical compound Cc1nc(CN(C2)C(C[n](c(-c3ccccc3)c3)nc3-c(cc3)ccc3OC(F)F)=O)c2[o]1 MBGYVBWDLLCVIS-UHFFFAOYSA-N 0.000 description 1
- ORIHICNHXWLDMB-UHFFFAOYSA-N Cc1nc(CN(C2)C(C[n](c(-c3ccccc3)c3)nc3-c3ccccc3)=O)c2[s]1 Chemical compound Cc1nc(CN(C2)C(C[n](c(-c3ccccc3)c3)nc3-c3ccccc3)=O)c2[s]1 ORIHICNHXWLDMB-UHFFFAOYSA-N 0.000 description 1
- VAHVVRTYPREPCX-UHFFFAOYSA-N Cc1nc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c(cc2C)ccc2OC)=O)n[o]1 Chemical compound Cc1nc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c(cc2C)ccc2OC)=O)n[o]1 VAHVVRTYPREPCX-UHFFFAOYSA-N 0.000 description 1
- UIWFGBVFLINNMX-UHFFFAOYSA-N Cc1nnc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c(nc2)ccc2OC(F)F)=O)[o]1 Chemical compound Cc1nnc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c(nc2)ccc2OC(F)F)=O)[o]1 UIWFGBVFLINNMX-UHFFFAOYSA-N 0.000 description 1
- ZECHEUBKXWVFTK-UHFFFAOYSA-N Cc1nnc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c2ccc(C(F)F)cc2)=O)[o]1 Chemical compound Cc1nnc(N(CC2)CCN2C(C[n](c(-c2ccccc2)c2)nc2-c2ccc(C(F)F)cc2)=O)[o]1 ZECHEUBKXWVFTK-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- YVKNDMKBGNDQGK-UHFFFAOYSA-N Fc1cc(CCN(C2)C(C[n]3nc(C4C=CC=CC4)cc3-c3ccccc3)C3CC3)c2cc1 Chemical compound Fc1cc(CCN(C2)C(C[n]3nc(C4C=CC=CC4)cc3-c3ccccc3)C3CC3)c2cc1 YVKNDMKBGNDQGK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102100032508 Histamine H3 receptor Human genes 0.000 description 1
- 101001016833 Homo sapiens Histamine H3 receptor Proteins 0.000 description 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 description 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 description 1
- 102000007205 Muscarinic M2 Receptor Human genes 0.000 description 1
- 108010008407 Muscarinic M2 Receptor Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- AFXZYYQISQTSSO-UHFFFAOYSA-N NCC(CC1)CCc2c1c(-c1ccccc1)ncn2 Chemical compound NCC(CC1)CCc2c1c(-c1ccccc1)ncn2 AFXZYYQISQTSSO-UHFFFAOYSA-N 0.000 description 1
- QOBLEAUFGZKEKU-UHFFFAOYSA-N NN(CC1)CC=C1c([o]1)ccc1I Chemical compound NN(CC1)CC=C1c([o]1)ccc1I QOBLEAUFGZKEKU-UHFFFAOYSA-N 0.000 description 1
- YXFOYJAGRABZHW-UHFFFAOYSA-N NN(CC1)CC=C1c([s]1)ccc1I Chemical compound NN(CC1)CC=C1c([s]1)ccc1I YXFOYJAGRABZHW-UHFFFAOYSA-N 0.000 description 1
- USNOUZMMVGMFNC-UHFFFAOYSA-N NN(CC1)Cc(cc2)c1cc2F Chemical compound NN(CC1)Cc(cc2)c1cc2F USNOUZMMVGMFNC-UHFFFAOYSA-N 0.000 description 1
- PANQCLBTHZIUFP-UHFFFAOYSA-N NN(CC1)Cc2c1c(F)ccc2F Chemical compound NN(CC1)Cc2c1c(F)ccc2F PANQCLBTHZIUFP-UHFFFAOYSA-N 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- UVWMNPNCAPZWLG-UHFFFAOYSA-N Oc1nc(-c2ccccc2)nc(CC2)c1CN2C(C[n](c(C1C=CC=CC1)c1)nc1-c1ccccc1)=C1CC1 Chemical compound Oc1nc(-c2ccccc2)nc(CC2)c1CN2C(C[n](c(C1C=CC=CC1)c1)nc1-c1ccccc1)=C1CC1 UVWMNPNCAPZWLG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 description 1
- FSBLZKBNEABPPC-UHFFFAOYSA-N [2,2-dimethyl-3,3,3-tris[(2-sulfanylacetyl)oxy]propyl] 2-sulfanylacetate Chemical compound SCC(=O)OC(C(COC(CS)=O)(C)C)(OC(CS)=O)OC(CS)=O FSBLZKBNEABPPC-UHFFFAOYSA-N 0.000 description 1
- YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960003225 alaproclate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000008856 allosteric binding Effects 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- JQEJOIHBPADVSY-UHFFFAOYSA-N azepin-4-one;hydrochloride Chemical compound Cl.O=C1C=CC=NC=C1 JQEJOIHBPADVSY-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229960002507 benperidol Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- XSKKIFJNZPNVGO-UHFFFAOYSA-N benzyl 2,5-dihydropyrrole-1-carboxylate Chemical compound C1C=CCN1C(=O)OCC1=CC=CC=C1 XSKKIFJNZPNVGO-UHFFFAOYSA-N 0.000 description 1
- HPZMDVORENWALF-UHFFFAOYSA-N benzyl 4-amino-2-benzyl-5-hydroxyazepane-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N1CCC(O)C(N)CC1CC1=CC=CC=C1 HPZMDVORENWALF-UHFFFAOYSA-N 0.000 description 1
- PDWYFMYGWHITCX-UHFFFAOYSA-N benzyl 4-amino-5-hydroxyazepane-1-carboxylate Chemical compound C1CC(O)C(N)CCN1C(=O)OCC1=CC=CC=C1 PDWYFMYGWHITCX-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229950010365 bicifadine Drugs 0.000 description 1
- OFYVIGTWSQPCLF-NWDGAFQWSA-N bicifadine Chemical compound C1=CC(C)=CC=C1[C@@]1(CNC2)[C@H]2C1 OFYVIGTWSQPCLF-NWDGAFQWSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229950002871 blonanserin Drugs 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N c1c(cccc2)c2c[nH]1 Chemical compound c1c(cccc2)c2c[nH]1 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N c1cnc2[n]1cccc2 Chemical compound c1cnc2[n]1cccc2 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N c1n[nH]c2ncccc12 Chemical compound c1n[nH]c2ncccc12 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N c1nc(ncnc2)c2[nH]1 Chemical compound c1nc(ncnc2)c2[nH]1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229950004826 capromorelin Drugs 0.000 description 1
- KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229950003930 femoxetine Drugs 0.000 description 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960003532 fluspirilene Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940076716 ibutamoren mesylate Drugs 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229950002473 indalpine Drugs 0.000 description 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- CWFAFDCTBAYTFA-UHFFFAOYSA-M lithium;2-propylpentanoate Chemical compound [Li+].CCCC(C([O-])=O)CCC CWFAFDCTBAYTFA-UHFFFAOYSA-M 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001861 melperone Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AQYAHPDSJAFBOS-UHFFFAOYSA-N methyl 2,4-dioxo-4-phenylbutanoate Chemical compound COC(=O)C(=O)CC(=O)C1=CC=CC=C1 AQYAHPDSJAFBOS-UHFFFAOYSA-N 0.000 description 1
- HHUNWJWOJPWLNK-UHFFFAOYSA-N methyl 2-methylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(C)=C1 HHUNWJWOJPWLNK-UHFFFAOYSA-N 0.000 description 1
- MSEBQGULDWDIRW-UHFFFAOYSA-N methyl 4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1 MSEBQGULDWDIRW-UHFFFAOYSA-N 0.000 description 1
- DAAJDWKBFWTVTM-UHFFFAOYSA-N methyl 5,6-dimethylpyridine-2-carboxylate Chemical compound COC(=O)C1=CC=C(C)C(C)=N1 DAAJDWKBFWTVTM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- JEUXZUSUYIHGNL-UHFFFAOYSA-N n,n-diethylethanamine;hydrate Chemical compound O.CCN(CC)CC JEUXZUSUYIHGNL-UHFFFAOYSA-N 0.000 description 1
- LSFRFLVWCKLQTO-UHFFFAOYSA-N n,n-dimethyl-4-[(4-nitrophenyl)diazenyl]aniline Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C([N+]([O-])=O)C=C1 LSFRFLVWCKLQTO-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 108010052671 nicotinic receptor alpha4beta2 Proteins 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 229950004193 perospirone Drugs 0.000 description 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- TUDHHJQPQZFEIH-UHFFFAOYSA-N piperidine-4,4-diol Chemical compound OC1(O)CCNCC1 TUDHHJQPQZFEIH-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 210000003538 post-synaptic density Anatomy 0.000 description 1
- 108010092804 postsynaptic density proteins Proteins 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 229960000957 prothipendyl Drugs 0.000 description 1
- JTTAUPUMOLRVRA-UHFFFAOYSA-N prothipendyl Chemical group C1=CN=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JTTAUPUMOLRVRA-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- VFBLZUKENILTIR-UHFFFAOYSA-N tert-butyl 2-(methylamino)-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepine-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=C1N=C(NC)S2 VFBLZUKENILTIR-UHFFFAOYSA-N 0.000 description 1
- ZCFXZIIXWPBFQV-UHFFFAOYSA-N tert-butyl 2-acetamido-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepine-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=C1N=C(NC(=O)C)S2 ZCFXZIIXWPBFQV-UHFFFAOYSA-N 0.000 description 1
- HVNRUPVNASOKCF-UHFFFAOYSA-N tert-butyl 2-methyl-3-oxo-5,6,8,9-tetrahydropyridazino[3,4-d]azepine-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=CC(=O)N(C)N=C21 HVNRUPVNASOKCF-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- CLLIETKJMDQBBH-UHFFFAOYSA-N tert-butyl 4-(4-methyl-1,3-oxazol-2-yl)piperazine-1-carboxylate Chemical compound CC1=COC(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 CLLIETKJMDQBBH-UHFFFAOYSA-N 0.000 description 1
- YMRIGBILXIVTOJ-UHFFFAOYSA-N tert-butyl 4-(5-propan-2-yl-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate Chemical compound O1C(C(C)C)=NN=C1C1CCN(C(=O)OC(C)(C)C)CC1 YMRIGBILXIVTOJ-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- UDXYSITZZMTXMH-UHFFFAOYSA-N tert-butyl 4-pyrimidin-2-yl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2N=CC=CN=2)=C1 UDXYSITZZMTXMH-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 description 1
- 229950009970 tesofensine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- WTFFOOAJSDVASL-UHFFFAOYSA-N tributyl(pyrimidin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CC=N1 WTFFOOAJSDVASL-UHFFFAOYSA-N 0.000 description 1
- VHKIEYIESYMHPT-UHFFFAOYSA-N triethyl(methoxycarbonylsulfamoyl)azanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)S(=O)(=O)NC(=O)OC VHKIEYIESYMHPT-UHFFFAOYSA-N 0.000 description 1
- QDNCLIPKBNMUPP-UHFFFAOYSA-N trimethyloxidanium Chemical compound C[O+](C)C QDNCLIPKBNMUPP-UHFFFAOYSA-N 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- Glutamate is the primary excitatory amino acid in the mammalian central nervous system. Neurotransmission mediated by glutamate has been demonstrated to be critical in many physiological processes, such as synaptic plasticity, long term potentiation involved in both learning and memory as well as sensory perception ( Riedel et al., Behav. Brain Res. 2003, 140:1-47 ). Furthermore, it has been demonstrated that an imbalance of glutamate neurotransmission plays a critical role in the pathophysiology of various neurological and psychiatric diseases.
- the excitatory neurotransmission of glutamate is mediated through at least two different classes of receptors, the ionotropic glutamate receptors (NMDA, AMPA and kainate) and the metabotropic glutamate receptors (mGluR).
- the ionotropic receptors are ligand gated ion channels and are thought to be responsible for the regulating rapid neuronal transmission between two neurons.
- the metabotropic glutamate receptors are G-protein coupled receptors (GPCRs) which appear to mediate not only synaptic transmission, but also to regulate the extent of neurotransmitter release as well as post synaptic receptor activation.
- mGluR5 belongs to a superfamily of currently eight identified Type III GPCRs, which are unique in that the glutamate ligand binds to a large extracellular amino-terminal protein domain. This superfamily is further divided into three gropus (Group I, II and III) based on amino acid homology as well as the intracellular signalling cascades they regulate ( Schoepp et al., Neuropharma, 1999, 38:1431-1476 ).
- mGluR5 belongs to group I and is coupled to the phospholipase C signalling cascade which regulates intracellular calcium mobilization.
- CNS mGluR5 has been demonstrared to be expressed mainly in the cortex, hippocampus, nucleus accumbens and the caudate-putamen. These brain regions are known to be involved in memory formation and cogntive function as well as emotional response.
- mGluR5 has been shown to be localized post-synaptically, adjacent to the post-synaptic density ( Lujan et al., Eur. J. Neurosci. 1996, 8: 1488-1500 ).
- mGluR5 A functional interaction between mGluR5 and the NMDA receptor has also been demonstrated, where activation of mGluR5 potentiates the activation state of the NMDA receptor ( Mannaioni et al, NeuroSci., 2001, 21:5925-5924 , Rosenbrock et al., Eur. J. Pharma., 2010, 639:40-46 ). Furthermore, activation of mGluR5 has been demonstrated in pre-clinical in vivo models to rescue cognitive impairment as well as psychotic disturbance induced by NMDA receptor antagonists ( Chan et al., Psychopharma. 2008, 198:141-148 ).
- mGluR5 activation of mGluR5, and thereby potentiation or normalization of the NMDA receptor signaling, is a potential mechanism for the treatment of psychiatric and neurological disorders.
- Most agonists of mGluR5 bind the orthosteric glutamate binding site. Since the glutamate binding site between the mGluR family members is highly conserved, it has been challenging to develop selective mGluR5 agonists which have acceptable CNS penetration and demonstrate in vivo activity.
- An alternative approach to achieve selectivity between the mGluR family members is to develop compounds which bind to an allosteric site, which is not as highly conserved between the family members. These allosteric binding compounds would not interfere with the natural glutamate binding and signaling, but modulate the receptor activation state.
- mGluR5 positive allosteric modulators of mGluR5 have recently been identified ( O'Brien et al., Mol. Pharma. 2003, 64: 731-740 , Lindsley et al., J. Med. Chem 2004, 47: 5825-5828 ). These compounds potentiate mGluR5 activity in the presence of bound glutamate. In the absence of bound glutamate, the mGluR5 positive modulators do not demonstrate intrinsic activity. Therefore, these compounds potentiate the natural signaling of mGluR5 as opposed to agonists which activate the receptor in a permanent, unnatural manner. mGluR5 positive allosteric modulators therefore represent an approach to potentiate mGluR5 signaling which in turn potentiates and normalizes the NMDA receptor hypofunction detected in neurological and psychiatric disorders.
- WO 03/051833 discloses heteroaryl substitued pyrazoles which are shown to be mGluR5 inhibitors.
- the present invention is directed to compounds of formula I in which
- C 1-6 -alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
- the last named subgroup is the radical attachment point, for example, the substituent "aryl-C 1-3 -alkyl-" means an aryl group which is bound to a C 1-3 -alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
- An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
- the numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.
- 3-carboxypropyl-group represents the following substituent: wherein the carboxy group is attached to the third carbon atom of the propyl group.
- the terms "1-methylpropyl-", “2,2-dimethylpropyl-” or “cyclopropylmethyl-” group represent the following groups:
- the asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
- a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc%) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- such salts include salts from ammonia, L-arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine (2,2'-iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-aminoethanol, ethylenediamine, N-ethyl-glucamine, hydrabamine, 1H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidine, sodium hydroxide, triethanolamine (2,2',2"-nitrilotris(ethanol)), tromethamine, zinc hydroxide, acetic acid, 2.2-dichloro-acetic acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid,
- salts can be formed with cations from metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like. (also see Pharmaceutical salts, Berge, S.M. et al., J. Pharm. Sci., (1977), 66, 1-19 ).
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
- Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention e.g. trifluoro acetate salts, also comprise a part of the invention.
- halogen generally denotes fluorine, chlorine, bromine and iodine.
- C 1-8 -alkyl either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms.
- C 1-5 -alkyl embraces the radicals H 3 C-, H 3 C-CH 2 -, H 3 C-CH 2 -CH 2 -, H 3 C-CH(CH 3 )-, H 3 C-CH 2 -CH 2 -CH 2 -, H 3 C-CH 2 -CH(CH 3 )-, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-C(CH 3 ) 2 -, H 3 C-CH 2 -CH 2 -CH 2 -CH 2 -, H 3 C-CH 2 -CH 2 -CH(CH 3 )-, H 3 C-CH 2 -CH(CH 3 )-, H 3 C-CH 2 -CH(CH 3 )-CH 2 -, H 3 C-CH(CH 3 )-CH 2 -
- C 2-n -alkenyl is used for a group as defined in the definition for "C 1-n -alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
- C 3-7 -cycloalkyl either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms.
- C 3-7 -cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- aryl denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated.
- Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.
- heteroaryl is intended to include all the possible isomeric forms.
- heteroaryl includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
- Aryl ketones were deprotonated with with potassium tert butoxide and condensed with a methylesters to form a di- keton.Then, the di-keton was condensed with hydrazine to yield a pyrazole-system.
- the pyrazoles were coupled with 2-bromoacetic acid methyl ester under basic conditions to yield the desired pyrazol-1-yl-acetic acid methyl ester together with different quantities of the isomeric systhem.
- the pyrazol-1-yl-acetic acid methyl ester was hydrolyzed with LiOH to the coresponding acid. The isomeres were either seperated before ore after hydrolysis of the ester.
- the pyrazol-1-yl-acetic acides were coupled with an amine to the desired products.
- the positive modulation of mGluR5 is measured in a HEK 293 cell line expressing human recombinant mGluR5 and is detected with calcium based FLIPR assay.
- the cells are cultured with DMEM supplemented with 10% FCS, 2 ⁇ g/mL tetracycline, 100 ⁇ g/mL hygromycin and 500 ⁇ /mL gneticin.
- the cell culture media is exchanged for tetracycline-free cell culture media 3-7 days before the assay.
- One day before the assay the cell culture medium is exchanged to DMEM without glutamine and phenol red and supplemented with 10% FCS, 100 ⁇ /mL hygromycin and 500 ⁇ /mL geneticin.
- the medium of the subconfluent cultures is removed and the cells are detached by addition of 2.5 ml EDTA(0.02%) per 175 cm2 culture flask for 1 minute.
- the cells are resuspend in Ringer solution (140 mM NaCl, 5 mM KCl 2.5 mM CaCl2, 1.5 mM MgCl2, 5 mM Glucose, 10 mM Hepes; adjusted to pH 7.4 with NaOH), pooled and Ringer solution added to adjust the volume to 50 mL.
- the cell suspension is centrifuged for 5 min at 1500U/min (425g).
- the supernatant is removed and the cells washed a second time with 50 ml fresh Ringer solution and centrifuged again as before. The supernatant is again removed and the pellet resuspended in Ringer solution to 1,000,000cells/ml (1x10 ⁇ 6 cells / mL).
- the cells are plated onto BD BioCoat Poly-D-Lysine 384 well plates (20.000 cells/well; 20 ⁇ l/well). The lid covered plates are then incubated until use at 37°C/10% CO2.
- 20 ⁇ l of Calcium-4 assay kit solution (prepared according to the manufacturer's description in Ringer solution) are added to the cells and the plates are incubated for 80 min 37°C and then 10 min at room temperature.
- Test compounds are dissolved and diluted in DMSO to 100-fold the desired concentrations.
- the compounds are diluted in Ringer solution such that the compounds are 4-fold more concentrated than the desired final assay concentration.
- the final DMSO concentration was 1%.
- the peak height of the Ca release related fluorescence signal (9-66) is used for the EC50.
- the EC50 of the modulation is calculated over a nonlinear regression with GraphPad Prism (Table 1). Table 1 Example EC50 [nM] Example EC50 [nM] Example EC50 [nM] Example EC50 [nM] 7.01.001 1429 7.01.080 277 7.02.061 96 7.02.139 101 7.01.002 592 7.01.081 30 7.02.062 323 7.02.140 51 7.01.003 1785 7.01.082 66 7.02.063 1728 7.02.141 138 7.01.004 390 7.01.083 86 7.02.064 177 7.02.142 27 7.01.005 381 7.01.084 34 7.02.065 194 7.02.143 48 7.01.006 870 7.01.085 26 7.02.066 24 7.02.144 68 7.01.007 1539 7.01.086 274 7.02.067 6 7.02.145 15 7.01.008 1184 7.01.087 125 7.02.068
- the present invention is directed to compounds of general formula I which are useful in the treatment of a disease and/or condition wherein the activity of an mGluR5 positive modulator is of therapeutic benefit, including but not limited to the treatment of psychotic disorders, cognitive disorders and dementias.
- the compounds of general formula I are useful for the treatment of psychotic disorders including schizophrenia, schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses, post stroke dementia, deficits in concentration, mild cognitive impairment, the cognitive dysfunction in Alzheimers disease, and the cognitive dysfunction of schizophrenia.
- the present invention also relates to a compound of general formula I as a medicament.
- a further aspect of the present invention relates to a compound of general formula I for the use in the treatment of a disease and/or condition wherein the activity of mGluR5 positive modulator is of therapeutic benefit.
- the present invention relates to a compound of general formula I for the use in the treatment of psychotic disorders, cognitive disorders and dementias.
- the present invention relates to a compound of general formula I for the use in the treatment of psychotic disorders including schizophrenia, schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses, post stroke dementia, deficits in concentration, mild cognitive impairment, the cognitive dysfunction in Alzheimers disease, and the cognitive dysfunction of schizophrenia.
- the present disclosure relates to methods for the treatment or prevention of above mentioned diseases and conditions, which method comprises the administration of an effective amount of a compound of general formula I to a human being.
- the dose range of the compounds of general formula I applicable per day is usually from 0.1 to 5000 mg, preferably from 0.1 to 1000 mg, more preferably from 5 to 500 mg, most preferably, 10 or 100 mg.
- Each dosage unit may conveniently contain from 0.1 to 500 mg, preferably 10 to 100 mg.
- the actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a pharmaceutically effective amount to be delivered based upon patient's unique condition.
- Suitable preparations for administering the compounds of formula will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders etc.
- the content of the pharmaceutically active compound(s) should be in the range from 1 to 99 wt.-%, preferably 10 to 90 wt.-%, more preferably 20 to 70 wt.-%, of the composition as a whole.
- Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula I with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
- excipients for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
- the tablets may also consist of several layers.
- a further aspect of the invention is a pharmaceutical formulation including a compound of formula I in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
- the present invention relates to a combination therapy in which an active compound according to the present invention is administered together with another active compound.
- the invention also refers to pharmaceutical formulations that provide such a combination of active ingredients, whereby one of which is an active compound of the present invention.
- Such combinations may be fixed dose combinations (the active ingredients that are to be combined are subject of the same pharmaceutical formulation) or free dose combinations (active ingredients are in separate pharmaceutical formulations).
- a further aspect of the present invention refers to a combination of each of the active compounds of the present invention, preferably at least one active compound according to the present invention, with another active compound for example selected from the group of antipsychotics such as haloperidol, clozapine, risperidone, quetiapine, aripripazole, and olanzapine; antidepressants such as selective serotonin re-uptake inhibitors and dual serotonin/noradrenaline re-uptake inhibitors; mood stabilizers such as lithium valproate and lamotrigine; beta-secretase inhibitors; gamma-secretase inhibitors; gamma-secretase modulators; amyloid aggregation inhibitors such as e.g.
- scyllo-inositol directly or indirectly acting neuroprotective and/or disease-modifying substances; anti-oxidants, such as e.g. vitamin E , ginko biloba or ginkolide; anti-inflammatory substances, such as e.g. Cox inhibitors, NSAIDs additionally or exclusively having Aß (Abeta) lowering properties; HMG-CoA reductase inhibitors, such as statins; acetylcholine esterase inhibitors, such as donepezil, rivastigmine, tacrine, galantamine; NMDA receptor antagonists such as e.g.
- anti-oxidants such as e.g. vitamin E , ginko biloba or ginkolide
- anti-inflammatory substances such as e.g. Cox inhibitors, NSAIDs additionally or exclusively having Aß (Abeta) lowering properties
- HMG-CoA reductase inhibitors such as statins
- AMPA receptor agonists AMPA receptor positive modulators
- AMPkines glycine transporter 1 inhibitors
- monoamine receptor reuptake inhibitors substances modulating the concentration or release of neurotransmitters; substances inducing the secretion of growth hormone such as ibutamoren mesylate and capromorelin; CB-1 receptor antagonists or inverse agonists; antibiotics such as minocyclin or rifampicin; PDE1, PDE2, PDE4, PDE5, PDE9 or PDE10 inhibitors, GABAA receptor inverse agonists; GABAA alpha5 receptor inverse agonists; GABAA receptor antagonists; nicotinic receptor agonists or partial agonists or positive modulators; alpha4beta2 nicotinic receptor agonists or partial agonists or positive modulators; alpha7 nicotinic receptor agonists or partial agonists; histamine receptor H3 antagonists; 5-HT4 receptor agonists or partial agonists;
- the active compounds according to the invention may also be used in combination with immunotherapies such as e.g. active immunisation with Abeta or parts thereof or passive immunisation with humanised anti-Abeta antibodies, nanobodies or antibody fragments for the treatment of the above mentioned diseases and conditions.
- immunotherapies such as e.g. active immunisation with Abeta or parts thereof or passive immunisation with humanised anti-Abeta antibodies, nanobodies or antibody fragments for the treatment of the above mentioned diseases and conditions.
- the active compounds according to the invention also may be combined with antipsychotics like haloperidol, flupentixol, fluspirilene, chlorprothixene, prothipendyl, levomepromazine, clozapine, olanzapine, quetiapine, risperidone, paliperidone, amisulpride, ziprasidone, aripiprazol, sulpiride, zotepine, sertindole, fluphenazine, perphenazine, perazine, promazine, chlorpromazine, levomepromazine, benperidol, bromperidol, pimozid, melperone, pipamperone, iloperidone, asenapine, perospirone, blonanserin, lurasidone.
- antipsychotics like haloperidol, flupentixol, fluspirilene, chlorprothixene,
- the active compounds according to the invention also may be combined with antidepressants like amitriptyline imipramine hydrochloride, imipramine maleate, lofepramine, desipramine, doxepin, trimipramine.
- antidepressants like amitriptyline imipramine hydrochloride, imipramine maleate, lofepramine, desipramine, doxepin, trimipramine.
- the active compounds according to the invention also may be combined with serotonin (5-HT) reuptake inhibitors such as alaproclate, citalopram escitalopram, clomipramine, duloxetine, femoxetine, fenfluramine, norfenfluramine, fluoxetine, fluvoxamine, indalpine, milnacipran, paroxetine, sertraline, trazodone, venlafaxine, zimelidine, bicifadine, desvenlafaxine, brasofens
- the combinations according to the present invention may be provided simultaneously in one and the same dosage form, i.e. in form of a combination preparation, for example the two components may be incorporated in one tablet, e. g. in different layers of said tablet.
- the combination may be also provided separately, in form of a free combination, i.e. the active compounds of the present invention are provided in one dosage form and one or more of the above mentioned combination partners is provided in another dosage form.
- These two dosage forms may be equal dosage forms, for example a co-administration of two tablets, one containing a therapeutically effective amount of the active compound of the present invention and one containing a therapeutically effective amount of the above mentioned combination partner. It is also possible to combine different administration forms, if desired. Any type of suitable administration forms may be provided.
- the active compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may be used simultaneously or at staggered times, but particularly close together in time. If administered simultaneously, the two active substances are given to the patient together; if administered at staggered times the two active substances are given to the patient successively within a period of less than or equal to 12, particularly less than or equal to 6 hours.
- the dosage or administration forms are not limited, in the frame of the present invention any suitable dosage form may be used.
- the dosage forms may be selected from solid preparations such as patches, tablets, capsules, pills, pellets, dragees, powders, troches, suppositories, liquid preparations such as solutions, suspensions, emulsions, drops, syrups, elixirs, or gaseous preparations such as aerosols, sprays and the like.
- the dosage forms are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of each active component being present. Depending from the administration route and dosage form the ingredients are selected accordingly.
- the dosage for the above-mentioned combination partners may be expediently 1/5 of the normally recommended lowest dose up to 1/1 of the normally recommended dose.
- the dosage forms are administered to the patient for example 1, 2, 3, or 4 times daily depending on the nature of the formulation. In case of retarding or extended release formulations or other pharmaceutical formulations, the same may be applied differently (e.g. once weekly or monthly etc.). It is preferred that the active compounds of the invention be administered either three or fewer times, more preferably once or twice daily.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
- Disclosed are substituted pyrazoles and their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment.
- Glutamate is the primary excitatory amino acid in the mammalian central nervous system. Neurotransmission mediated by glutamate has been demonstrated to be critical in many physiological processes, such as synaptic plasticity, long term potentiation involved in both learning and memory as well as sensory perception (Riedel et al., Behav. Brain Res. 2003, 140:1-47). Furthermore, it has been demonstrated that an imbalance of glutamate neurotransmission plays a critical role in the pathophysiology of various neurological and psychiatric diseases.
- The excitatory neurotransmission of glutamate is mediated through at least two different classes of receptors, the ionotropic glutamate receptors (NMDA, AMPA and kainate) and the metabotropic glutamate receptors (mGluR). The ionotropic receptors are ligand gated ion channels and are thought to be responsible for the regulating rapid neuronal transmission between two neurons. The metabotropic glutamate receptors are G-protein coupled receptors (GPCRs) which appear to mediate not only synaptic transmission, but also to regulate the extent of neurotransmitter release as well as post synaptic receptor activation.
- Disregulation in glutamatergic neurotransmission, for example through altered glutamate release or post-synaptic receptor activation, has been demonstrated in a variety of neurological ans well as psychiatric disorders. Hypofunction of the NMDA receptor has not only been demonstrated in Alzheimer's patients, but is increasingly accepted as the putative cause of schizophrenia (Farber et al., Prog. Brain Res., 1998, 116: 421-437, Coyle et al., Cell. and Mol Neurobiol. 2006, 26: 365-384). This is supported by clinical studies showing that antagonists of the NMDA receptor induce symptoms indistinguishable to those suffered by schizophrenia patients (Javitt et al., Am J. Psychiatry, 1991, 148: 1301-1308). Therefore, approaches that could potentiate or normalize NMDA receptor signallng have the potential to treat neurological and psychiatric disorders. mGluR5 belongs to a superfamily of currently eight identified Type III GPCRs, which are unique in that the glutamate ligand binds to a large extracelullar amino-terminal protein domain. This superfamily is further divided into three gropus (Group I, II and III) based on amino acid homology as well as the intracellular signalling cascades they regulate (Schoepp et al., Neuropharma, 1999, 38:1431-1476). mGluR5 belongs to group I and is coupled to the phospholipase C signalling cascade which regulates intracellular calcium mobilization. In the CNS, mGluR5 has been demonstrared to be expressed mainly in the cortex, hippocampus, nucleus accumbens and the caudate-putamen. These brain regions are known to be involved in memory formation and cogntive function as well as emotional response. mGluR5 has been shown to be localized post-synaptically, adjacent to the post-synaptic density (Lujan et al., Eur. J. Neurosci. 1996, 8: 1488-1500). A functional interaction between mGluR5 and the NMDA receptor has also been demonstrated, where activation of mGluR5 potentiates the activation state of the NMDA receptor (Mannaioni et al, NeuroSci., 2001, 21:5925-5924, Rosenbrock et al., Eur. J. Pharma., 2010, 639:40-46). Furthermore, activation of mGluR5 has been demonstrated in pre-clinical in vivo models to rescue cognitive impairment as well as psychotic disturbance induced by NMDA receptor antagonists (Chan et al., Psychopharma. 2008, 198:141-148). Therefore, activation of mGluR5, and thereby potentiation or normalization of the NMDA receptor signaling, is a potential mechanism for the treatment of psychiatric and neurological disorders. Most agonists of mGluR5 bind the orthosteric glutamate binding site. Since the glutamate binding site between the mGluR family members is highly conserved, it has been challenging to develop selective mGluR5 agonists which have acceptable CNS penetration and demonstrate in vivo activity. An alternative approach to achieve selectivity between the mGluR family members is to develop compounds which bind to an allosteric site, which is not as highly conserved between the family members. These allosteric binding compounds would not interfere with the natural glutamate binding and signaling, but modulate the receptor activation state. Positive allosteric modulators of mGluR5 have recently been identified (O'Brien et al., Mol. Pharma. 2003, 64: 731-740, Lindsley et al., J. Med. Chem 2004, 47: 5825-5828). These compounds potentiate mGluR5 activity in the presence of bound glutamate. In the absence of bound glutamate, the mGluR5 positive modulators do not demonstrate intrinsic activity. Therefore, these compounds potentiate the natural signaling of mGluR5 as opposed to agonists which activate the receptor in a permanent, unnatural manner. mGluR5 positive allosteric modulators therefore represent an approach to potentiate mGluR5 signaling which in turn potentiates and normalizes the NMDA receptor hypofunction detected in neurological and psychiatric disorders.
-
US 2005/256130 discloses aryl piperazines. -
WO 03/051833 -
- R1
- represents phenyl, methyl, ethyl, propyl, iso-propyl, cyclopropyl, cyclohexyl,
- X
- represents
- Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.
- In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C1-6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named subgroup is the radical attachment point, for example, the substituent "aryl-C1-3-alkyl-" means an aryl group which is bound to a C1-3-alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
- In case a compound of the present invention is depicted in form of a chemical name and as a formula in case of any discrepancy the formula shall prevail.
- An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
- The numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.
-
- The asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
- Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc...) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
- The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
- As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include salts from ammonia, L-arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine (2,2'-iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-aminoethanol, ethylenediamine, N-ethyl-glucamine, hydrabamine, 1H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidine, sodium hydroxide, triethanolamine (2,2',2"-nitrilotris(ethanol)), tromethamine, zinc hydroxide, acetic acid, 2.2-dichloro-acetic acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 2,5-dihydroxybenzoic acid, 4-acetamido-benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, decanoic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, ethylenediaminetetraacetic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, D-glucoheptonic acid, D-gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycine, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, DL-lactic acid, lactobionic acid, lauric acid, lysine, maleic acid, (-)-L-malic acid, malonic acid, DL-mandelic acid, methanesulfonic acid, galactaric acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, octanoic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid (embonic acid), phosphoric acid, propionic acid, (-)-L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid. Further pharmaceutically acceptable salts can be formed with cations from metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like. (also see Pharmaceutical salts, Berge, S.M. et al., J. Pharm. Sci., (1977), 66, 1-19).
- The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
- Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention (e.g. trifluoro acetate salts,) also comprise a part of the invention.
- The term halogen generally denotes fluorine, chlorine, bromine and iodine.
- The term "C1-8-alkyl", either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms. For example the term C1-5-alkyl embraces the radicals H3C-, H3C-CH2-, H3C-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C-CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-, H3C-CH2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)-and H3C-CH2-CH(CH2CH3)-.
- The term "C2-n-alkenyl", is used for a group as defined in the definition for "C1-n-alkyl" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
- The term "C3-7-cycloalkyl", either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms. For example the term C3-7-cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- The term "aryl" as used herein, either alone or in combination with another radical, denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated. Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.
- The term "heteroaryl" means a mono- or polycyclic-ring systems containing one or more heteroatoms selected from N, O or S(O)r, wherein r=0, 1 or 2, consisting of 5 to 14 ring atoms wherein at least one of the heteroatoms is part of aromatic ring. The term "heteroaryl" is intended to include all the possible isomeric forms.
-
- Many of the terms given above may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.
- Compounds of the present invention can be prepared in accordance with techniques that are well known to those skilled in the art.
-
- Aryl ketones were deprotonated with with potassium tert butoxide and condensed with a methylesters to form a di- keton.Then, the di-keton was condensed with hydrazine to yield a pyrazole-system. The pyrazoles were coupled with 2-bromoacetic acid methyl ester under basic conditions to yield the desired pyrazol-1-yl-acetic acid methyl ester together with different quantities of the isomeric systhem. The pyrazol-1-yl-acetic acid methyl ester was hydrolyzed with LiOH to the coresponding acid. The isomeres were either seperated before ore after hydrolysis of the ester. Finally, the pyrazol-1-yl-acetic acides were coupled with an amine to the desired products.
- The positive modulation of mGluR5 is measured in a HEK 293 cell line expressing human recombinant mGluR5 and is detected with calcium based FLIPR assay. The cells are cultured with DMEM supplemented with 10% FCS, 2 µg/mL tetracycline, 100 µg/mL hygromycin and 500 µ/mL gneticin. The cell culture media is exchanged for tetracycline-free cell culture media 3-7 days before the assay. One day before the assay the cell culture medium is exchanged to DMEM without glutamine and phenol red and supplemented with 10% FCS, 100 µ/mL hygromycin and 500 µ/mL geneticin. On the assay day, the medium of the subconfluent cultures is removed and the cells are detached by addition of 2.5 ml EDTA(0.02%) per 175 cm2 culture flask for 1 minute. The cells are resuspend in Ringer solution (140 mM NaCl, 5 mM KCl 2.5 mM CaCl2, 1.5 mM MgCl2, 5 mM Glucose, 10 mM Hepes; adjusted to pH 7.4 with NaOH), pooled and Ringer solution added to adjust the volume to 50 mL. The cell suspension is centrifuged for 5 min at 1500U/min (425g). The supernatant is removed and the cells washed a second time with 50 ml fresh Ringer solution and centrifuged again as before. The supernatant is again removed and the pellet resuspended in Ringer solution to 1,000,000cells/ml (1x10^6 cells / mL). The cells are plated onto BD BioCoat Poly-D-Lysine 384 well plates (20.000 cells/well; 20 µl/well). The lid covered plates are then incubated until use at 37°C/10% CO2. For dye loading, 20 µl of Calcium-4 assay kit solution (prepared according to the manufacturer's description in Ringer solution) are added to the cells and the plates are incubated for 80 min 37°C and then 10 min at room temperature.
- Controls, Compound dilution and assay execution:
- Each assay plate contained wells with "high" and "low" controls:
- Low controls 1%DMSO/ringer solution + basal glutamate activation (defined as 100% CTL).
- High controls 10µM CDPPB + basal glutamate activation (defined as 200% CTL).
- Test compounds are dissolved and diluted in DMSO to 100-fold the desired concentrations. In a second step, the compounds are diluted in Ringer solution such that the compounds are 4-fold more concentrated than the desired final assay concentration. The final DMSO concentration was 1%.
- 20µl of each compound solution are then transferred to the assay plate and the Ca2+ kinetic is measured to determine any intrinsic compound activity. After 5 min incubation in the FLIPR device, the second stimulation with 20 µl of glutamate in Ringer solution (glutamate concentration adjusted to approximately 5% basal stimulation of the maximal possible glutamate effect) is added and the kinetic Ca2+ response of the wells was measured for the modulation effect.
- The peak height of the Ca release related fluorescence signal (9-66) is used for the EC50. The EC50 of the modulation is calculated over a nonlinear regression with GraphPad Prism (Table 1).
Table 1 Example EC50 [nM] Example EC50 [nM] Example EC50 [nM] Example EC50 [nM] 7.01.001 1429 7.01.080 277 7.02.061 96 7.02.139 101 7.01.002 592 7.01.081 30 7.02.062 323 7.02.140 51 7.01.003 1785 7.01.082 66 7.02.063 1728 7.02.141 138 7.01.004 390 7.01.083 86 7.02.064 177 7.02.142 27 7.01.005 381 7.01.084 34 7.02.065 194 7.02.143 48 7.01.006 870 7.01.085 26 7.02.066 24 7.02.144 68 7.01.007 1539 7.01.086 274 7.02.067 6 7.02.145 15 7.01.008 1184 7.01.087 125 7.02.068 199 7.02.146 295 7.01.009 1535 7.01.088 29 7.02.069 187 7.02.147 572 7.01.010 695 7.01.089 22 7.02.070 40 7.02.148 15 7.01.011 1974 7.01.090 240 7.02.071 71 7.02.149 42 7.01.012 829 7.01.091 37 7.02.072 251 7.02.150 28 7.01.013 617 7.01.092 33 7.02.073 627 7.02.151 211 7.01.014 463 7.01.093 35 7.02.074 171 7.02.152 67 7.01.015 1805 7.01.094 90 7.02.075 318 7.02.153 15 7.01.016 143 7.01.095 53 7.02.076 293 7.02.154 108 7.01.018 538 7.01.096 22 7.02.077 1799 7.02.155 92 7.01.019 1661 7.01.097 109 7.02.078 232 7.02.156 170 7.01.020 258 7.01.098 477 7.02.079 182 7.02.157 430 7.01.021 1530 7.02.001 55 7.02.080 321 7.02.158 116 7.01.022 511 7.02.002 1175 7.02.081 991 7.02.159 44 7.01.023 166 7.02.003 925 7.02.082 291 7.02.160 23 7.01.024 1157 7.02.004 689 7.02.083 35 7.02.161 35 7.01.025 1865 7.02.005 1256 7.02.084 73 7.02.162 120 7.01.026 503 7.02.006 1954 7.02.085 42 7.02.163 122 7.01.027 1022 7.02.007 600 7.02.086 11 7.02.164 46 7.01.028 1303 7.02.008 997 7.02.087 28 7.02.165 18 7.01.029 796 7.02.009 220 7.02.088 254 7.02.166 149 7.01.030 484 7.02.010 13 7.02.089 59 7.02.167 370 7.01.031 1865 7.02.011 37 7.02.090 41 7.02.168 604 7.01.032 710 7.02.012 47 7.02.091 115 7.02.169 20 7.01.033 1531 7.02.013 92 7.02.092 369 7.02.170 30 7.01.034 398 7.02.014 21 7.02.093 120 7.02.171 68 7.01.035 205 7.02.015 15 7.02.094 49 7.02.172 64 7.01.036 1322 7.02.016 110 7.02.095 6 7.02.173 38 7.01.037 188 7.02.017 68 7.02.096 10 7.02.174 39 7.01.038 359 7.02.018 693 7.02.097 8 7.02.175 59 7.01.039 752 7.02.019 36 7.02.098 12 7.02.176 221 7.01.041 1550 7.02.020 21 7.02.099 18 7.02.177 111 7.01.042 285 7.02.021 55 7.02.100 4 7.02.178 69 7.01.043 40 7.02.022 11 7.02.101 14 7.02.179 236 7.01.044 1853 7.02.023 12 7.02.102 27 7.02.180 1070 7.01.045 689 7.02.024 29 7.02.103 34 7.02.181 398 7.01.046 1002 7.02.025 148 7.02.104 48 7.02.182 65 7.01.047 789 7.02.026 83 7.02.105 242 7.02.183 330 7.01.048 573 7.02.027 58 7.02.106 10 7.02.184 132 7.01.049 652 7.02.028 943 7.02.107 39 7.02.185 258 7.01.050 652 7.02.029 329 7.02.108 127 7.02.186 326 7.01.051 1441 7.02.030 1761 7.02.109 61 7.02.187 1610 7.01.052 31 7.02.031 1244 7.02.110 156 7.02.188 19 7.01.053 914 7.02.032 37 7.02.111 334 7.02.189 15 7.01.054 53 7.02.033 29 7.02.112 404 7.02.190 29 7.01.055 53 7.02.034 42 7.02.113 637 7.02.191 80 7.01.056 253 7.02.035 35 7.02.114 29 7.02.192 82 7.01.057 740 7.02.036 136 7.02.115 8 7.02.193 290 7.01.058 279 7.02.037 194 7.02.116 21 7.02.194 63 7.01.059 32 7.02.038 210 7.02.117 66 7.02.195 2 7.01.060 101 7.02.039 915 7.02.118 127 7.02.196 43 7.01.061 163 7.02.040 1696 7.02.119 12 7.02.197 90 7.01.062 242 7.02.041 1216 7.02.120 21 7.02.198 6 7.01.063 334 7.02.042 192 7.02.121 49 7.02.199 16 7.01.064 1230 7.02.043 1736 7.02.122 38 7.02.200 24 7.01.065 173 7.02.044 735 7.02.123 71 7.02.201 171 7.01.066 153 7.02.045 1411 7.02.124 68 7.02.202 19 7.01.067 122 7.02.046 881 7.02.125 253 7.02.203 178 7.01.068 236 7.02.047 221 7.02.126 68 7.02.204 47 7.01.069 380 7.02.048 31 7.02.127 200 7.02.205 18 7.01.070 128 7.02.049 157 7.02.128 140 7.02.206 6 7.01.071 233 7.02.050 183 7.02.128 159 7.02.207 70 7.01.072 245 7.02.051 190 7.02.129 156 7.02.208 36 7.01.073 84 7.02.052 297 7.02.130 57 7.02.209 61 7.01.074 91 7.02.053 552 7.02.131 8 7.02.210 145 7.01.075 87 7.02.054 186 7.02.132 186 7.02.211 13 7.01.076 412 7.02.055 42 7.02.133 276 7.02.212 3 7.01.077 110 7.02.056 245 7.02.134 15 7.02.213 26 7.01.078 78 7.02.057 913 7.02.135 45 7.02.214 11 7.01.079 447 7.02.058 750 7.02.136 141 7.02.215 9 7.02.218 54 7.02.059 287 7.02.137 352 7.02.216 6 7.02.219 209 7.02.060 760 7.02.138 44 7.02.217 56 7.02.220 290 7.02.231 19 7.02.242 45 7.02.253 41 7.02.221 4 7.02.232 104 7.02.243 164 7.02.254 281 7.02.222 23 7.02.233 280 7.02.244 48 7.02.255 7 7.02.223 13 7.02.234 200 7.02.245 236 7.02.256 11 7.02.224 2 7.02.235 30 7.02.246 62 7.02.257 16 7.02.225 17 7.02.236 69 7.02.247 172 7.02.258 31 7.02.226 11 7.02.237 111 7.02.248 290 7.02.259 10 7.02.227 35 7.02.238 146 7.02.249 184 7.02.260 26 7.02.228 398 7.02.239 842 7.02.250 65 7.02.229 31 7.02.240 85 7.02.251 34 7.02.230 878 7.02.241 76 7.02.252 69 - The present invention is directed to compounds of general formula I which are useful in the treatment of a disease and/or condition wherein the activity of an mGluR5 positive modulator is of therapeutic benefit, including but not limited to the treatment of psychotic disorders, cognitive disorders and dementias.
- The compounds of general formula I are useful for the treatment of psychotic disorders including schizophrenia, schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses, post stroke dementia, deficits in concentration, mild cognitive impairment, the cognitive dysfunction in Alzheimers disease, and the cognitive dysfunction of schizophrenia.
- Therefore, the present invention also relates to a compound of general formula I as a medicament.
- A further aspect of the present invention relates to a compound of general formula I for the use in the treatment of a disease and/or condition wherein the activity of mGluR5 positive modulator is of therapeutic benefit.
- Furthermore, the present invention relates to a compound of general formula I for the use in the treatment of psychotic disorders, cognitive disorders and dementias.
- Furthermore, the present invention relates to a compound of general formula I for the use in the treatment of psychotic disorders including schizophrenia, schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses, post stroke dementia, deficits in concentration, mild cognitive impairment, the cognitive dysfunction in Alzheimers disease, and the cognitive dysfunction of schizophrenia.
- The present disclosure relates to methods for the treatment or prevention of above mentioned diseases and conditions, which method comprises the administration of an effective amount of a compound of general formula I to a human being.
- The dose range of the compounds of general formula I applicable per day is usually from 0.1 to 5000 mg, preferably from 0.1 to 1000 mg, more preferably from 5 to 500 mg, most preferably, 10 or 100 mg. Each dosage unit may conveniently contain from 0.1 to 500 mg, preferably 10 to 100 mg.
- The actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a pharmaceutically effective amount to be delivered based upon patient's unique condition.
- Suitable preparations for administering the compounds of formula will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders etc. The content of the pharmaceutically active compound(s) should be in the range from 1 to 99 wt.-%, preferably 10 to 90 wt.-%, more preferably 20 to 70 wt.-%, of the composition as a whole. Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula I with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants. The tablets may also consist of several layers.
- A further aspect of the invention is a pharmaceutical formulation including a compound of formula I in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
- In another aspect the present invention relates to a combination therapy in which an active compound according to the present invention is administered together with another active compound. Accordingly, the invention also refers to pharmaceutical formulations that provide such a combination of active ingredients, whereby one of which is an active compound of the present invention. Such combinations may be fixed dose combinations (the active ingredients that are to be combined are subject of the same pharmaceutical formulation) or free dose combinations (active ingredients are in separate pharmaceutical formulations).
- Consequently, a further aspect of the present invention refers to a combination of each of the active compounds of the present invention, preferably at least one active compound according to the present invention, with another active compound for example selected from the group of antipsychotics such as haloperidol, clozapine, risperidone, quetiapine, aripripazole, and olanzapine; antidepressants such as selective serotonin re-uptake inhibitors and dual serotonin/noradrenaline re-uptake inhibitors; mood stabilizers such as lithium valproate and lamotrigine; beta-secretase inhibitors; gamma-secretase inhibitors; gamma-secretase modulators; amyloid aggregation inhibitors such as e.g. scyllo-inositol; directly or indirectly acting neuroprotective and/or disease-modifying substances; anti-oxidants, such as e.g. vitamin E , ginko biloba or ginkolide; anti-inflammatory substances, such as e.g. Cox inhibitors, NSAIDs additionally or exclusively having Aß (Abeta) lowering properties; HMG-CoA reductase inhibitors, such as statins; acetylcholine esterase inhibitors, such as donepezil, rivastigmine, tacrine, galantamine; NMDA receptor antagonists such as e.g. memantine; AMPA receptor agonists; AMPA receptor positive modulators, AMPkines, glycine transporter 1 inhibitors; monoamine receptor reuptake inhibitors; substances modulating the concentration or release of neurotransmitters; substances inducing the secretion of growth hormone such as ibutamoren mesylate and capromorelin; CB-1 receptor antagonists or inverse agonists; antibiotics such as minocyclin or rifampicin; PDE1, PDE2, PDE4, PDE5, PDE9 or PDE10 inhibitors, GABAA receptor inverse agonists; GABAA alpha5 receptor inverse agonists; GABAA receptor antagonists; nicotinic receptor agonists or partial agonists or positive modulators; alpha4beta2 nicotinic receptor agonists or partial agonists or positive modulators; alpha7 nicotinic receptor agonists or partial agonists; histamine receptor H3 antagonists; 5-HT4 receptor agonists or partial agonists; 5-HT6 receptor antagonists; alpha2-adrenoreceptor antagonists, calcium antagonists; muscarinic receptor M1 agonists or partial agonists or positive modulators; muscarinic receptor M2 antagonists; muscarinic receptor M4 antagonists; muscarinic receptor M4 positive allosteric modulators; metabotropic glutamate receptor 5 positive allosteric modulators; metabotropic glutamate receptor 2 antagonists; metabotropic glutamate receptor 2/3 agonists; metabotropic glutamate receptor 2 positive allosteric modulators and other substances that modulate receptors or enzymes in a manner such that the efficacy and/or safety of the active compounds according to the invention is increased and/or unwanted side effects are reduced.
- The active compounds according to the invention may also be used in combination with immunotherapies such as e.g. active immunisation with Abeta or parts thereof or passive immunisation with humanised anti-Abeta antibodies, nanobodies or antibody fragments for the treatment of the above mentioned diseases and conditions.
- The active compounds according to the invention also may be combined with antipsychotics like haloperidol, flupentixol, fluspirilene, chlorprothixene, prothipendyl, levomepromazine, clozapine, olanzapine, quetiapine, risperidone, paliperidone, amisulpride, ziprasidone, aripiprazol, sulpiride, zotepine, sertindole, fluphenazine, perphenazine, perazine, promazine, chlorpromazine, levomepromazine, benperidol, bromperidol, pimozid, melperone, pipamperone, iloperidone, asenapine, perospirone, blonanserin, lurasidone.
- The active compounds according to the invention also may be combined with antidepressants like amitriptyline imipramine hydrochloride, imipramine maleate, lofepramine, desipramine, doxepin, trimipramine.
Or the active compounds according to the invention also may be combined with serotonin (5-HT) reuptake inhibitors such as alaproclate, citalopram escitalopram, clomipramine, duloxetine, femoxetine, fenfluramine, norfenfluramine, fluoxetine, fluvoxamine, indalpine, milnacipran, paroxetine, sertraline, trazodone, venlafaxine, zimelidine, bicifadine, desvenlafaxine, brasofensme and tesofensine. - The combinations according to the present invention may be provided simultaneously in one and the same dosage form, i.e. in form of a combination preparation, for example the two components may be incorporated in one tablet, e. g. in different layers of said tablet. The combination may be also provided separately, in form of a free combination, i.e. the active compounds of the present invention are provided in one dosage form and one or more of the above mentioned combination partners is provided in another dosage form. These two dosage forms may be equal dosage forms, for example a co-administration of two tablets, one containing a therapeutically effective amount of the active compound of the present invention and one containing a therapeutically effective amount of the above mentioned combination partner. It is also possible to combine different administration forms, if desired. Any type of suitable administration forms may be provided.
- The active compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may be used simultaneously or at staggered times, but particularly close together in time. If administered simultaneously, the two active substances are given to the patient together; if administered at staggered times the two active substances are given to the patient successively within a period of less than or equal to 12, particularly less than or equal to 6 hours.
- The dosage or administration forms are not limited, in the frame of the present invention any suitable dosage form may be used. Exemplarily the dosage forms may be selected from solid preparations such as patches, tablets, capsules, pills, pellets, dragees, powders, troches, suppositories, liquid preparations such as solutions, suspensions, emulsions, drops, syrups, elixirs, or gaseous preparations such as aerosols, sprays and the like.
- The dosage forms are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of each active component being present. Depending from the administration route and dosage form the ingredients are selected accordingly.
- The dosage for the above-mentioned combination partners may be expediently 1/5 of the normally recommended lowest dose up to 1/1 of the normally recommended dose.
- The dosage forms are administered to the patient for example 1, 2, 3, or 4 times daily depending on the nature of the formulation. In case of retarding or extended release formulations or other pharmaceutical formulations, the same may be applied differently (e.g. once weekly or monthly etc.). It is preferred that the active compounds of the invention be administered either three or fewer times, more preferably once or twice daily.
- Unless otherwise stated, one or more tautomeric forms of compounds of the examples described hereinafter may be prepared in situ and/or isolated. All tautomeric forms of compounds of the examples described hereinafter should be considered to be disclosed.
- The invention is illustrated by way of the following examples, in which the following abbreviations may be employed:
-
- RT
- room temperature
- THF
- tetrahydrofuran
- KOtBu
- Potassium tert-butanolate
- PFTU
- pentafluorphenol-tetramethyluronium hexafluorophosphat
- ACN
- acetonitrile
- MeOH
- methanol
- DIPEA
- diisopropylamine
- DEA
- diethylamine
- EtOAC
- ethyl acetate
- DMF
- dimethylformamide
- TBTU
- [(Benzotriazol-1-yloxy)-dimethylamino-methylene]-dimethyl-ammonium tetrafluoro borate
- HATU
- (O-(7-Azobenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate
- conc.
- concentrated
- min.
- minutes
- DCM
- dichlormethane
- TFA:
- trifluoro acetic acid
- LDA
- lithium diisopropylamide
- Dess-Martin
- (1, 1, 1-triacetoxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one
- DDQ
- 2,3-dichlor-5,6-dicyan-p-benzochinon
- All compounds specified in the examples below gave the correct mass spectra matching the theoretical isotope pattern. For practical reasons, only one of the major isotope peaks is given as representative data for the mass spectrum.
- Gilson HPLC
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 00.00 90 10 50 02.00 90 10 50 11.00 0 100 50 14.00 0 100 50 - column: Sunfire C18, 30 x 100 mm, 10 µm (temperature: isocratic 60°C).
- Waters ZQ 2000MS, Agilent HP100, binäre pumps
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 1.50 1.30 0 100 1.50 2.50 0 100 1.50 2.60 95 5 1.50 - column: Sunfire C18, 4.6 x 50 mm, 3.5 µm (temperature: isocratic 40°C).
- diodenarray detection: 210-400 nm.
- Waters ZQ 2000MS, Agilent HP100, binäre pumps
-
- A: water with 0.10% TFA
- B: acetonitrile with 0.08% TFA
-
time in min %A %B flow in ml/min 0.00 95 5 1.50 2.00 0 100 1.50 2.50 0 100 1.50 2.60 95 5 1.50 - column: Sunfire C18, 4.6 x 50 mm, 3.5 µm (temperature: isocratic 40°C).
- diodenarray detection: 210-500 nm.
- Waters Acquity with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 99 1 1.20 0.05 99 1 1.20 1.05 0 100 1.20 1.25 0 100 1.20 - column: Sunfire C18, 2.1 x 30 mm, 2,5 µm (temperature: isocratic 60°C).
- diodenarray detektion: 210-400 nm.
- Waters Acquity with diodenarraydetector
-
- A: water with 0.13% TFA
- B: methanol with 0.05% TFA
-
time in min %A %B flow in ml/min 0.00 99 1 1.20 0.05 99 1 1.20 1.05 0 100 1.20 1.25 0 100 1.20 - Waters Alliance with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 4.90 1.60 0 100 4.90 2.20 95 5 4.90 - Waters Alliance with DA and MS-detector
-
- A: water with 0.10% NH3
- D: methanol
-
time in min %A %D flow in ml/min 0.00 95 5 4.00 0.20 95 5 4.00 1.50 0 100 4.00 1.75 0 100 4.00 - Waters ZQ 2000MS, Alliance 2695
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 1.50 1.30 0 100 1.50 3.00 0 100 1.50 3.40 95 5 1.50 - column: Sunfire C18, 4.6 x 50 mm, 3.5 µm (temperature: isocratic 40°C).
- diodenarray detection: 210-500 nm.
- Agilent 1200 System
-
- A: water with 0.10% formicacid
- B: acetonitril 0.10% formicacid
-
time in min %A %B flow in ml/min 0.00 95 5 1.60 0.10 95 5 1.60 1.75 5 95 1.60 1.90 5 95 1.60 1.95 95 5 1.60 2.00 95 5 1.60 - column: Zorbax StableBond C18, 3.0 x 30 mm, 1.8 µm (temperature: isocratic 25°C).
- detection: 254 nm.
- Waters Acquity with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 99 1 1.30 0.15 99 1 1.30 1.10 0 100 1.30 1.25 0 100 1.30 - column: Sunfire C18, 2.1 x 30 mm, 2,5 µm (temperature: isocratic 60°C).
- diodenarray detektion: 210-400 nm.
- Waters ZQ MS, Alliance 2690/2695 HPLC, Waters 996/2996 diodenarraydetector
-
- A: water with 0.10% TFA
- D: methanol
-
time in min %A %D flow in ml/min 0.00 95 5 4.00 0.20 95 5 4.00 1.60 0 100 4.00 2.10 0 100 4.00 - column: Waters XBridge™ C18 3.5nm, 4.6x20mm IS™ (temperature: isocratic 40°C).
- diodenarray detection: 210-400 nm.
- Agilent 1200 mit DA- und MS-Detektor
-
- A: water with 0.10% NH3
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 2.20 0.30 95 5 2.20 1.50 0 100 2.20 1.60 0 100 2.40 1.80 0 100 2.40 - Waters Alliance with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol with 0.10% TFA
-
time in min %A %B flow in ml/min 0.00 95 5 4.00 0.20 95 5 4.00 1.50 0 100 4.00 1.75 0 100 4.00 1.85 95 5 4.00 - Waters Acquity with diodenarraydetector and massdetector
-
- A: water with 0.13% TFA
- B: methanol with 0.08% TFA
-
time in min %A %B flow in ml/min 0.00 99 1 1.30 0.05 99 1 1.30 0.35 0 100 1.30 0.50 0 100 1.30 - column: Xbridge BEH C18, 2.1 x 30 mm, 1,7 µm (temperature: isocratic 60°C).
- diodenarray detektion: 210-400 nm.
- Waters Alliance with DA and MS-detector
-
- A: water with 0.10% NH3
- D: methanol with 0.10% NH3
-
time in min %A %D flow in ml/min 0.00 95 5 4.00 0.20 95 5 4.00 1.50 0 100 4.00 1.75 0 100 4.00 - Waters ZMD, Alliance 2690/2695 HPLC, Waters 996/2996 diodenarraydetector
-
- A: water with 0.10% TFA
- B: acetonitril with 0.10% TFA
-
time in min %A %B flow in ml/min 0.00 95 5 2.80 0.30 95 5 2.80 1.60 2 98 2.80 1.90 2 98 2.80 2.00 95 5 2.50 - Waters ZQ 2000MS, Agilent HP100, binäre pumps
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 80 20 2.00 1.70 0 100 2.00 2.50 0 100 2.00 2.60 80 20 2.00 - column: Sunfire C18, 4.6 x 50 mm, 3.5 µm (temperature: isocratic 60°C).
- diodenarray detection: 210-500 nm.
- Agilent 1100 with DA and MS-detector
-
- A: water with 0.1 % TFA
- D: methanol
-
time in min %A %D flow in ml/min 0.00 95 5 4.00 0.15 95 5 4.00 1.70 0 100 4.00 2.25 0 100 4.00 - column: Stable Bond C18 3.5µm, 4.6x30mm (temperature: isocratic 60°C).
- Agilent 1100 with DA and MS-detector
-
- A: water with 0.1 % TFA
- D: methanol with 0.1% TFA
-
time in min %A %D flow in ml/min 0.00 95 5 4.00 0.15 95 5 4.00 1.70 0 100 4.00 2.25 0 100 4.00 - Agilent 1200 with DA and MS-detector
-
- A: water with 0.2% TFA
- D: methanol
-
time in min %A %D flow in ml/min 0.00 95 5 2.20 0.05 95 5 2.20 1.40 0 100 2.20 1.80 0 100 2.20 - Waters Alliance with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 4.80 1.60 0 100 4.80 1.85 0 100 4.80 1.90 95 5 4.80 - Waters Acquity with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 99 1 1.40 0.05 99 1 1.40 1.00 0 100 1.40 1.25 0 100 1.40 - column: Xbridge C18, 2.1 x 20 mm, 2,5 µm (temperature: isocratic 60°C).
- diodenarray detektion: 210-400 nm.
- Agilent 1200 with DA and MS-detector
-
- A: water with 0.2% TFA
- D: methanol
-
time in min %A %D flow in ml/min 0.00 95 5 2.20 0.05 95 5 2.20 1.40 0 100 2.20 1.80 0 100 2.20 - Waters Alliance with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 4.00 1.60 0 100 4.00 1.85 0 100 4.00 1.90 95 5 4.00 - Waters Acquity with diodenarraydetector and massdetector
-
- A: water with 0.13% TFA
- B: methanol with 0.05% TFA
-
time in min %A %B flow in ml/min 0.00 99 1 1.30 0.05 99 1 1.30 0.35 0 100 1.30 0.50 0 100 1.30 - column: Xbridge BEH C18, 2.1 x 30 mm, 1,7 µm (temperature: isocratic 60°C).
- diodenarray detektion: 210-400 nm.
- Waters Alliance with diodenarraydetector and massdetector
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 4.00 1.60 0 100 4.00 1.85 95 5 4.00 1.90 95 5 4.00 - Waters Acquity with diodenarraydetector and massdetector
-
- A: water with 0.1 % TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 99 1 1.50 0.05 99 1 1.50 1.05 0 100 1.50 1.20 0 100 1.50 - Waters Acquity with diodenarraydetector and massdetector
-
- A: water with 0.1 % TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 99 1 1.50 0.05 99 1 1.50 1.00 0 100 1.50 1.10 0 100 1.50 - Waters Alliance with DA and MS-detector
-
- A: water with 0.10% NH3
- D: methanol with 0.10% NH3
-
time in min %A %D flow in ml/min 0.00 95 5 4.00 0.20 95 5 4.00 1.50 0 100 4.00 1.75 0 100 4.00 - Waters Alliance with diodenarraydetector and massdetector
-
- A: water with 0.10% NH3
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 4.00 0.20 95 5 4.00 1.50 0 100 4.00 1.75 0 100 4.00 - Waters SQD MS, Aquility UPLC, diodenarray: 210-500 nm
-
- A: water with 0.10% TFA
- B: acetonitrile with 0.08% TFA
-
time in min %A %B flow in ml/min 0.00 95 5 1.50 0.70 0 100 1.50 0.70 0 100 1.50 0.81 95 5 1.50 1.90 0 100 0.20 -
- Applied Biosystem: LCM/MS API 2000, HPLC: Shimadzu Prominence
- dual wavelength: 220 and 260 nm
-
- A: water with 0.05% TFA
- B: acetonitrile
-
time in min %A %B flow in ml/min 0.01 90 10 1.20 1.50 70 30 1.20 3.00 10 90 1.20 4.00 10 90 1.20 5.00 90 10 1.20 - Agilent 1200 with DA and MS-detector
-
- A: water with 0.2% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 1.80 0.05 95 5 1.80 1.70 0 100 1.80 1.75 0 100 2.50 -
- A: acetonitril 95% and water 5% with 0.1% TFA
- B: water 95% and acetonitril 5% with 0.1% TFA
-
time in min %A %B flow in ml/min 00.00 20 80 15.00 80 20 20.00 80 20 - Waters ZQ 2000MS, Agilent HP100, binäre pumps
-
- A: water with 0.10% TFA
- B: methanol
-
time in min %A %B flow in ml/min 0.00 95 5 1.50 1.30 0 100 1.50 2.50 0 100 1.50 2.60 95 5 1.50 - column: Sunfire C18, 4.6 x 50 mm, 3.5 µm (temperature: isocratic 60°C).
- diodenarray detection: 210-500 nm.
-
-
- 32 mL 62% HBr solution in 50 mL conc. acetic acid was added to 50 g hexahydro-azepin-4-on hydrochloride in 600 mL conc. acetic acid. Then 17.2 mL bromine in 50 mL conc. acetic acid was dropped to the reaction. The solvent was removed and the residue was crystallized from a mixture of DCM/ MeOH (8/2) to give 79 g of the desired compound. (M+H)+: 192
-
- 1.44 g thiourea was added to 4 g 5-bromo-azepan-4-one hydrobromide in 50 mL ethanol and stirred 3h at 80°C and over the weekend at RT. The precipitate was filltered and dried to yield 3.8 g of the product.
Rt: 0.61 min (method F)
(M+H)+: 170 -
-
- 3.1 g sodiummethanolate was added to 7.2 g 4, 6-dichlorpyrimidine in 150 mL methanol at 0°C. The reaction was warmed to RT and stirred additional 3h. Water and EtOAC were added and the layers were seperated. The organic layer was dried and evaporated to give 7.1 g of the desired product.
Rt: 0.85 min (method L), (M+H)+: 144 -
- 9.9 mL 1.6 mol/L n-buthyllithium solution in hexane was added to 3.85 g 2-tributylstannanyl-pyrimidine at -78°C. The reaction was stirred 30 min. at -78°C and 2.1 g 1- carboxylic acid tert-butyl ester-4-piperidone in 10 mL THF was added. The reaction was warmed up and stirred over night at RT. Then, the reaction was cooled to 0°C and water was added slowly. EtOAC was added and the layers were seperated. The organic layer was washed one time with water and two times with a saturated ammonia chloride solution. Then, the organic layer was dried and evaporated. The residue was purified by HPLC to yield 448 mg.
Rt: 1.21 min (method J), (M+H)+: 133/162/180 -
- 0.5 g tetrakis (triphenylphosphine) palladium was added to 1.3 g 4-chloro-6-methoxy-pyrimidine and 4-(4, 4, 5, 5-tetramethyl-(1, 3, 2) dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester) and 9 mL 2 mol/L sodiumcarbonate in 40 mL dioxane. The reaction was stirred 15 min. under microwave conditions. Water was added and the reaction was extracted with DCM. The organic layer was dried and evaporated. The residue was purified by HPLC to give 1.44g of the desired product.
Rt: 1.38 min (method L)
(M+H)+: 292 - By using the same synthesis strategy as for 4-(6-methoxy-pyrimidin-4-yl)-piperidine-1-carboxylic acid tert-butyl ester the following compound was obtained:
Examples Product MS m/z [M+H]+ HPLC Method Rt min 6.01.05.02 163//205/261 method J 1.02 6.01.06.02 292 method I 0.96 6.01.07.02 276 method I 0.82 6.01.08.02 280 method I 0.92 6.01.09.02 276 6.01.10.02 266 method I 0.86 6.01.11.02 281 method I 0.90 -
- 110 mg 4-hydroxy-4-pyrimidin-2-yl-piperidine-1-carboxylic acid tert-butyl ester was dissolved in 2.5 mL pyridine and 0.18 ml phosphoroxychloride was added. The reaction was stirred one day at RT. The reaction was decomposed with water and extracted with DCM. The organic layer was dried and the solvent was removed to give 84 mg of the desired compound.
Rt: 1.33 min (method J)
(M+H)+: 162/206/262 -
- 150 mg palladium charcoal was added to 765 mg 4-(6-methoxy-pyrimidin-4-yl)-3, 6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester in 90 mL methanol. The reaction was stirred 3.5 h at RT and 3 bar hydrogen. Then, the reaction was filltered and evaporated to give 769 mg of the desired product.
Rt: 1.31 min (method J)
(M+H)+: 194/238/294 - By using the same synthesis strategy as for 4-(6-methoxy-pyrimidin-4-yl)-piperidine-1-carboxylic acid tert-butyl ester the following compound was obtained:
Examples Product MS m/z [M+H]+ HPLC Method Rt min 6.01.05.03 263//207/163 method J 1.04 6.01.06.03 294 method I 0.91 6.01.11.03 283 method I 0.86 -
- 1.16 g 4-(6-Methoxy-pyrimidin-4-yl)-piperidine-1-carboxylic acid tert-butyl ester were stirred in 2 mL 4 mol/L HCl solution in dioxane for 40 min. The mixture was diluted with dioxane and basified with sodiumcarbonate. The suspension was filtered and the filtrate was concentrated to give 0.24 g of the desired product.
Rt: 1.31 min (method L)
(M+H)+: 194/238/294 - By using the same synthesis strategy as for 1', 2', 3', 4', 5', 6'-hexahydro-(2,4') bipyridinyl hydrochlorid the following compounds were obtained:
Examples Product MS m/z [M+H] + HPLC Method Rt min 6.01.05 263/207/163 method J 1.04 6.01.06 194 method I 0.45 6.01.07 176 method F 0.87 6.01.08 180 method F 0.96 6.01.09 176 method F 0.95 6.01.10 166 method F 0.44 6.01.11 183 method I 0.35 6.01.15 181 method I 0.52 -
- 4.7 mL 33% HBr in acetic acid, 11.4 g bromine in 30 mL acetic acid was added slowly to a stirred solution of 10 g piperidine-4,4-diol in 60 mL acetic acid at RT. The reaction mixture was stirred additional 45 min at ambient temperature and the acetic acid was completely removed under reduced pressure. The residue was dissolved in 200 mL acetone and refluxed for 1 hour, cooled, filtered and washed with acetone and dried to give 15.2 g of the desired product (M+H)+: 180.
-
- 4.55 g thiourea was added to 15.2 g 3-Bromo-piperidin-4-one hydrobromide in 152 mL ethanol and refluxed for 20h. The reaction was cooled and the solid was filtered, washed with ethanol and dried to give 15.8 g of the desired product.
(M+H)+: 184 -
- 15.8 g 4, 5, 6, 7-tetrahydro-thiazolo (5, 4-c) pyridin-2-ylamine and 100 mL dioxane was added to 15.2 g potassium carbonate in 158 mL water. 13.1 g di tert-butyl dicarbonate in 58 mL dioxane was added at 0°C. The reaction mixture was allowed to stir for 3h at ambient temperature. The reaction mixture was diluted with water and the solid was filtered through silica gel, washed with water (2 x 50 mL) to afford the desired product. The filtrate was concentrated, diluted with water and extracted with ethyl acetat. The organic layer was dried over magnesium sulfate and concentrated to afford 11.6 g desired product.
1H NMR (400 MHz, DMSO-d6): δ 1.41 (s, 9H), 2.43 (t, 2H), 3,56 (t, 2H), 4.28 (s, 2H), 6.80 (s, 2H)
(M+H)+: 256 -
-
- 39 g calcium carbonate and 36.8 g phenyl chloroformate in 250 mL THF was added to a stirred solution of 50 g 2-amino-6, 7-dihydro-4H-thiazolo (5, 4-c)pyridine-5-carboxylic acid tert-butyl ester in 1L THF. The reaction mixture was allowed to stir for 15h. The reaction mixture was filtered through silica gel and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate and the organic layer was dried over magnesium sulfate. The organic layer was concentrated under reduced pressure. The residue was washed with 20% ethyl acetate in hexane to give 60 g of the desired product.
1H NMR (400 MHz, CDCl3): δ 1.44 (s, 9H), 2.81 (s, 2H), 3.66 (s, 2H), 4.53 (s, 2H), 7.18 (d, 2H), 7.25 - 7.30 (m, 1H), 7.41 (t, 2H), 11.99 (br s, 1H)
(M+H)+: 376 -
- 45 mg allylamin was added to 200 mg 2-phenoxycarbonylamino-6, 7-dihydro-4H-thiazolo (5, 4-c) pyridine-5-carboxylic acid tert-butyl ester in 25 mL DMF. The reaction was stirred for 12h at RT, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine solution and concentrated. The residue was purified by column chromatographie (silica gel, eluent: 40% ethylacetate in hexane) to give 179 mg of desired product. (M+H)+: 339
-
- 10 % TFA in 60 ml chloroform was added to 2.5 g 2-(3-allyl-ureido)-6, 7-dihydro-4H-thiazolo (5, 4-c) pyridine-5-carboxylic acid tert-butyl ester in 28 ml chloroform and stirred for 2 h at RT. The mixture was concentrated, the residue was diluted with chloroform and basified with 2.5 M aqueous potassium carbonate solution and extracted wih chloroform. The organic layer was concentrated. The residue was washed with a mixture 50% ethyl acetate and 50% hexane to yield 1.7 g of the desired product. (M+H)+: 239
-
- 95 mg acetyl chloride was added to 312 mg 2-Amino-4, 5, 7, 8-tetrahydro-thiazolo (4, 5-d) azepine-6-carboxylic acid tert-butyl ester in 5 mL pyridine at 15°C. The reaction was stirred 3h at RT. The reaction was diluted with dichlormethane and 1mL water was added. The solution was filtered over 40 mL Alox and 100 mL Extrelut and evaporated to give 127 mg desired product. (M+H)+: 312
-
-
-
- 137 mL Diisopropylamine in 3390 mL THF was cooled to 0°C and 360 mL n-buthyllithium was added dropwise under nitrogen. The reaction was cooled to -78°C and a solution of 180 mL piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester in 1800 mL THF was added dropwise over 1h. The reaction was stirred at -78°C for 2h and then 168 mL methyliodide in 300 mL THF was added in one portion. The mixture was stirred 2h at -78°C and then allowed to warm to RT. The reaction was quenched with saturated aqueous sodium sulfate solution, the organig phase was seperated, dried and evaporated. The residue was purified by chromatography on silica gel to give 155 g of the desired product.
Rf: 0.3 (petrolether/EtOAC= 10/1)
1H NMR (TH03330-021-1, 400 MHz, CDCl3): δ3.67-3.65 (m, 2H, CH2), 3.62 (s, 3H, CH3), 2.93-2.87 (m, 2H, CH2), 2.00-1.95 (m, 2H, CH2), 1.37 (s, 9H, 3CH3), 1.31-1.25 (m, 2H, CH2), 1.12 (s, 3H, CH3). -
- 100 g 4-methyl-piperidine-1, 4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester was dissolved in 100 mL methanol and 300 mL hydrazine monohydrate was added. The mixture was reflux overnight. The reaction was cooled to RT and then concentrated to dryness under vacuum to give compound 89 g desired product.
Rf: 0.2 (DCM/ MeOH= 20/1) - By using the same synthesis strategy as for 4-hydrazinocarbonyl-4-methyl-piperidine-1-carboxylic acid tert-butyl ester the following compound was obtained:
Examples Product NMR Rf 6.01.19.02 1NMR: (400 MHz, MeOD): δ 4.08 (d, J = 13.2 Hz, 2H, CH2), 2.27 (br, 2H, NH2), 2.38-2.29 (m, 1H, CH), 1.72-1.68 (m, 2H, CH2), 1.63-1.56 (m, 2H, CH2), 1.45 (s, 9H, 3CH3). 0.2 (DCM/ MeOH= 20/1) -
- 30 g 4-hydrazinocarbonyl-4-methyl-piperidine-1-carboxylic acid tert-butyl ester was refluxed with 150 mL 1, 1, 1-trimethoxy-2-methyl-propane overnight. The excess of reagent was removed under vaccuum and the residue was purified by chromatography on silica gel to give 19 g of the desired product.
1H NMR (TH03330-027-1, 400 MHz, CDCl3): δ 3.76-3.75 (m, 2H, CH2), 3.31-3.30 (m, 1H, CH), 3.22-3.17 (m, 2H, CH2), 2.18-2.15 (m, 2H, CH2), 1.68-1.62 (m, 2H, CH2), 1.45-1.38 (m, 9H, BocH), 1.37 (s, 9H, CH3). - By using the same synthesis strategy as for 4-(5-isopropyl-(1, 3, 4) oxadiazol-2-yl)-4-methyl-piperidine-1-carboxylic acid tert-butyl ester the following compound was obtained:
Examples Product NMR Rf 6.01.19.03 1H-NMR (400 MHz, MeOD): δ 4.08-4.04 (m, 2H, CH2), 3.20-3.13 (m, 2H, 2CH), 3.01 (br, 2H, CH2), 2.07-2.03 (m, 2H, CH2), 1.75-1.68 (m, 2H, CH2), 1.46 (s, 9H, 3CH3), 1.36 (d, J = 6.8 Hz, 6H, 2CH3). 0.3 (DCM/ MeOH= 20/1) -
- 150 mL saturated dioxane-HCl was added to 19 g 4-(5-isopropyl-(1, 3, 4) oxadiazol-2-yl)-4-methyl-piperidine-1-carboxylic acid tert-butyl ester in 100 mL dioxane at 0°C. The mixture was stirred at RT for 2 h. The precipitate was filtered and washed with ethyl acetate to give 15.1 g of the desired product.
1H NMR (TH03335-030-4, 400 MHz, MeOD): δ 3.38-3.33 (m, 2H, CH2), 3.22-3.16 (m, 1H, CH), 3.13-3.10 (m, 2H, CH2), 2.44-2.39 (m, 2H, CH2), 2.03-1.95 (m, 2H, CH2), 1.46 (s, 3H, CH3), 1.38 (d, J = 7.2 Hz, 6H, 2CH3). - By using the same synthesis strategy as for 4-(5-isopropyl-(1, 3, 4) oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester the following compound was obtained:
Examples Product MS m/z [M+H]+ 6.01.19 1H-NMR (400 MHz, MeOD): δ 3.49-3.44 (m, 2H, CH2), 3.38-3.34 (m, 1H, CH), 3.22-3.16 (m, 3H, CH2/CH), 2.36-2.32 (m, 2H, CH2), 2.09-2.02 (m, 2H, CH2), 1.37 (d, J = 7.2 Hz, 6H, CH3). -
- 104 mg 60% sodium hydrid was added to 700 mg 2-amino-4, 5, 7, 8-tetrahydro-thiazolo (4, 5-d) azepine-6-carboxylic acid tert-butyl ester in 1.5 mL THF at 0°C. Then, 162 µL methyliodide was dropped to the mixture. The reaction was stirred over night at RT. The solvent was removed and the residue was purified by HPLC and 121 mg of the desired product was obtained. (M+H)+: 284
-
-
- 136.6 g brombenzol in 300 mL diethylether was added to 21.2 g magnesium in 100 mL diethylether. The Grignard reaction is initiated with a small amount of iodine, kept at reflux by adding the bromebenzole and stirred additional 15 min for compleation. Then, 21.2 g 1-benzyl-5-chloro-2, 3, 6, 7-tetrahydro-1H-azepine-4-carbaldehyde in 300 mL diethylether was added. The mixture was stirred 2h in a warm water bath and quenched with 200 ml 6 M HCl solution at 0°C. The reaction was filtered and the filtrate was washed wih diethylether and water. The filtrate was disolved in sodium carbonate solution and chloroform. The layers were seperated and the organic layer was washed with water and evaporated to give 89.9 g of the desired product. Fp:124°C
-
- 89 g (1-benzyl-5-chloro-2, 3, 6, 7-tetrahydro-1H-azepin-4-yl)-phenyl-methanol in 800 mL dichlormethane was dropped to 115.4 g pyridiniumchlorchromate in 600 mL dichlormethane. The reaction was stirred 2.5 days at RT. Potassiumcarbonate-solution was added to the reaction. The mixture was stirred 2h at RT and filtered over celite. The layers were seperated and the organic layer was washed with water. The solvent was removed and the residue was purified by chromatography on silica gel (toluol/EE: 8.5:1.5). The solvent was removed and 64.6 g of the desired compound was obtained. Rf: 0.5 (toluol/EE: 8.5:1.5)
-
- 16.8 g sodium was added to 500 mL ethanol at 10°C. Then, 48.5 g formamidine hydrochloride was added and the reaction was stirred 15 min at 6°C. 28 g (1-benzyl-5-chloro-2, 3, 6, 7-tetrahydro-1H-azepin-4-yl)-phenyl-methanone was added and the reaction was stirred 17.5 h at RT and 1h at 40°C. The mixture was filtered and the solvent was removed. The residue was dissolved in ethyl acetate. The layers were seperated and the organic layer was washed with water and evaporated. The residue was crystalysed with diethylether to yield 10.7 g of the desired product. Fp: 81-82°C
-
- Palladium charcoal was added to 17 g 7-benzyl-4-phenyl-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-d] azepine in 250 mL ethanol and 54 mL 1 mol/L HCl solution. The reaction was stirred at 80°C and 5 bar hydrogen. The mixture was filltered and evaporated to give 13.15 g of the desired product.
-
-
- 289 g 1-amino-propan-2-ol was added to 75 g isonicotinoyl chloride and 549 mL triethylamine in 2 L anhydrous dichlormethane at 0°C under nitrogen atmosphere. After 30 min at 0 °C the reaction was concentrated under vacuum and the residue was re-suspended in 5 L ethyl acetate. The precipitate was removed by filtration. The filtrate was concentrate and recrystallized from ethyl acetate to give 154 g of the desired product.
Rf: 0.4 (dichlormethane:20/methanol:1)
(M+H)+: 181 -
- A solution of 154 g N-(2-hydroxy-propyl)-isonicotinamide in 800 mL dichlormethane was added dropwise to a solution of 438 g Dess-Martin reagent in 1.2 L dichlormethane at 0 °C under nitrogen atmosphere. After 30 min at 0 °C, the solution was stirred at RT for 4 h. The mixture was concentrated under vacuum and the resulting crude product was purified by flash chromatography (silica gel) to give 91 g of the desired product.
Rf: 0.55 (dichlormethane/methanol:20/1), (M+H)+: 179 -
- 20 g N-(2-oxo-propyl)-isonicotinamide was dissolved in 200 mL phosphoroxychloride at 0°C and the mixture was heated to 120 °C overnight. The reaction was quenched with cold water and then extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated under vacuum. The resulting crude product was purified by flash chromatography (silica gel) to give compound 10.5 g of the desired product.
Rf: 0.35 (petrolether/ethyl acetate:1/1), (M+H)+: 167 -
-
Rf: 0.00 (petrolether/ethyl acetate:1/1), (M+H)+: 252 -
- 21.6 g sodium borohydride was added to 130 g 1-benzyl-4-(5-methyl-oxazol-2-yl)-pyridinium in 1.5 L ethanol at 0 °C under nitrogen atmosphere. After 30 min at 0 °C, the solution was stirred at RT for 2 h. The mixture was concentrated and treated with water and ethyl acetate. The organic layers were separated and aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum. The resulting crude product was purified by flash chromatography (silica gel) to give 81.2 g of the desired product. Rf: 0.3 (petrolether/ethyl acetate:1/1), (M+H)+: 255
-
- 20 g 1-chloroethyl chloroformate was added to 24 g 1-benzyl-4-(5-methyl-oxazol-2-yl)-1, 2, 3, 6-tetrahydro-pyridine in 200 mL anhydrous dichlormethane at 0 °C under nitrogen atmosphere. After 2 h, the solution was concentrated and 200 mL anhydrous methanol was added. The mixture was heated at reflux for 4 h and concentrated. The resulting crude product was recrystallized from dichlormethane to give 16 g of the desired product.
Rf 0.0 (petrolether/ethyl acetate:1/1)
(M+H)+: 165 -
- 77.4 ml 2 mol/L trimethylsilyldiazomethan in hexane was added to 5, 6-dimethyl-pyridine-2-carboxylic acid in 150 mL methanol and 600 mL dichlormethane at -5 °C and the reaction was stirred for 0.5h. After warming to RT the solvent was removed and the residue was purified by chromatorgaphie on Silica (cyclohexane/ethyl acetate: 7/ 3) to give 12.8 g of the desired product. Rt: 0.49 (method M), (M+H)+: 166
-
- 5 g 2-methyl-isonicotinic acid was stirred 24 h at 50°C in 150 mL 1.3 mol/L HCl in methanol. The solvent was removed and water was added to the residue. The mixture was basified with saturated sodiumhydrogencarbonate solution and extracted with ethylacetate. The organic layer was dried with magnesiumsulfate and evaporated to give 4.5 g of the desired product.
Rt: 0.36 (method S), (M+H)+: 152 -
-
Rt: 1.13 (method AB), (M+H-56)+: 156 -
- 5.3 mL triethylamine and 2.6 g hydroxylamine hydrochloride were added to 6.8 g 4-cyano-piperazine-1-carboxylic acid tert-butyl ester in 50 mL ethanol. The reaction was stirred 2h at 80 °C. The solvent was removed and 50 mL pyridine and 3.7 mL acetic anhydride were added to the residue and stirred at 80 °C over night. The mixture was evaporated. Water was added and the precipitate was filtered and purified by chromatography on silica gel (cyclohexane/ethyl acetate: 2/1) to give 3.35 g of the desired product.
Rt: 1.30 (method AB), (M+H)+: 269 -
- 20 mL 4 mol/L HCl solution in dioxane was added to 3.35 g 4-(5-methyl-(1, 2, 4) oxadiazol-3-yl)-piperazine-1-carboxylic acid tert-butyl ester dissolved in 20 mL dioxane was stirred over night. The mixture was diluted with diethylether and the precipitate was filtered and washed with diethylether to give 2.5 g of the desired product.
Rt: 0.72 min (method AB), (M+H)+: 169 -
-
- 17 mL 2 mol/L aqueous sodium hydroxide solution was dropped to 6.7 g 4-cyano-piperazine-1-carboxylic acid tert-butyl ester and 2.5 mL 1-hydroxy-propan-2-one in 10 mL THF. The reaction was stirred 12h at RT and over night at 75°C. The reaction was coolded, water was added and the mixture was diluted with diethylether. The precipitate was filtered to give 1.32 g of the desired product.
Rt: 1.30 min. (method AB)
(M+H)+: 269 -
- 80.9 mL 1 mol/L zinc chloride solution in diethylether was dropped to 11.4 g 4-cyanopiperazine-1-carboxylic acid tert-butyl ester. The reaction was stirred over night at 150°C. The precipitate was filtered and the filtrate was concentrated and purified by chromatography on silica gel (dichlormethane/methanol/ammonia: 9/1/0.1%). Diethylether was added to the residue and the precipitate was filtered to give 1 g of the desired product. The residue was dissolved in diethylether and hydrogen chloride in was added. The precipitate was filttered to give 0.9 g of the desired product.
Rt: 0.67min (method F)
(M+H)+: 169 -
-
- The compound was produced according to patent application
EP 18499770 A1 -
- 43 mL benzyloxycarbonyl chloride in 135 mL dichlormethane was added to 17.6 g 1-benzyl-2,5-dihydro-1H-pyrrole in 135 mL dichlormethane at 0 °C in 60 min. The mixture was stirred 3h at RT and washed with saturated sodium hydrogencarbonate solution. The organic layer was dried and evaporated. The residue was purified by chromatography on silica gel (hexane/ethyl acetate: 5/1) to give 19.7 g of the desired product.
Rt: 16.50 min. (method AG)
(M+H)+: 204 -
- The compound was produced according patent application
WO2004/99201 A1 -
- 6.5 g benzyl 6-oxa-3-azabicyclo [3.1.0] hexane-3-carboxylate in 80 mL 33% aqueous ammonia solution was stirred 20h in a closed vessel. The reaction was cooled and extracted with dichlormethane. The organic layer was was washed with sodium chloride solution and evaporated to give 6.1g of the desired product.
Rt: 2.37min. (method AG)
(M+H)+: 237 -
- 3.24 g acetic anhydride was added to 7.1 g benzyl 3-amino-4-hydroxypyrrolidine-1-carboxylate in 100 mL dichlormethane at 0-5 °C. The mixture was stirred 2h at RT, 100 mL diethylether was added and the mixture was stirred for 15 min. The precipitate was filtered to give 7.6 g of the desired product.
Rt: 4.14min. (method AG)
(M+H)+: 279 -
- Pyidin-sulphur trioxide in 6.5 mL DMSO was added to 1.34 g benzyl-3-acetamido-4-hydroxypyrrolidine-1-carboxylate and 2.5 mL DIPEA in 8 mL dichlormethane at 0 °C. The reaction was stirred 1h at RT. Water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with water and sodium chloride solution and evaporated. The residue was purified by chromatography on silica gel (ethyl acetate) to give 1.1 g of the desired product. (M+H)+: 277
-
- 8.5 g methoxycarbonylsulfamoyl) triethylammoniumhydroxid was added to 4.7 g benzyl 3-acetamido-4-oxopyrrolidine-1-carboxylate in 180 mL THF. The reaction was stirred 1h at 65 °C and evaporated. The residue was purified on silica gel (hexane/ethyl acetate: 1/1) to give 1.4 g of the desired product.
Rt: 1.29 min (method Y), (M+H)+: 259 -
- 0.6 mL trimethylsilyliodide was added to 400 mg 2-methyl-4, 6-dihydro-pyrrolo [3, 4-d] oxazole-5-carboxylic acid benzyl ester in 30 mL acetonitrile. The reaction was stirred 4h at RT. The solvent was removed to give 390 mg of the desired product.
Rt: 0.49 min (method AB)
(M+H)+: 125 -
- 18 g 2-bromo-5-fluoro-4-methyl-pyridine, 1.5 g 1, 1'-bis (diphenylphosphino) ferrocene dichloropalladium (II) and 18 g sodium acetate was stirred 17 h at 80°C in an atmosphere of 5 bar carbon monoxide. The reaction was filtered and the solvent was removed. Diethylether was added to the residue and the mixture was filtered. The filtrate was evaporated to give 12 g of the desired product.
Rt: 0.90 min. (method W)
(M+H)+: 170 -
-
-
- 6.7 g potassium carbonate was added to 7 g 5-oxo-azepane-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester in 50 mL DMF and stirred at RT. After 30 min 6.1 g ethyl bromoacetate was added and the reaction was stirred at RT over night. The reaction was diluted with water and extracted with ethyl acetate/hexane (1/1). The organic phase was washed with brine, dried and concentrated. The residue was purified by column chromatography on silica gel (15% ethyl acetate in hexane) to give 5.6 g of the desired product.
(M+H)+= 372 -
- 23.3 g sodium hydroxide in 218 mL water was added to 38 g 4-ethoxycarbonylmethyl-5-oxo-azepane-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester in 155 mL THF. The reaction was stirred over night at RT, THF was removed and the mixture was extracted with dichlormethane. The aqueous part was acidified with 3M HCl to pH 3 at 0 °C. The aqueous solution was extracted with dichloromethane, dried over magnesium sulfate, concentrated under reduced pressure to give 18.2 g of the desired product.
(M+H)+=272 -
- 60 mL acetic acid was added to 16 g 4-carboxymethyl-5-oxo-azepane-l-carboxylic acid tert-butyl ester in 120 mL THF at 5 °C. 14 mL hydrazine hydrate was added to the reaction and the mixture was refluxed over night. After completion of the reaction, volatiles were removed and the residue was basified with sodium carbonate and extracted with chloroform. The organic layer was dried and concentrated under reduced pressure to afford 11 g of the desired product (M+H)+=268
-
- 7 g 3-oxo-2, 3, 4, 4a, 5, 6, 8, 9-octahydro-1, 2, 7-triaza-benzocycloheptene-7-carboxylic cid tert-butyl ester was dissolved in 70 mL toluene and 6.7 g manganese dioxide was added to the reaction mixture. It was heated at reflux for 48h. After completion of the reaction, the reaction mixture was diluted with chloroform and filtered through celite. The filtrate was concentrated and purified by column chromatography to afford 5.5 g of the desired product., (M+H)+= 266
-
- 11 g 3-oxo-2, 3, 5, 6, 8, 9-hexahydro-1, 2, 7-triaza-benzocycloheptene-7-carboxylic acid ert-butyl ester in 90 ml phosphor oxychloride was refluxed overnight. The phosphor oxychloride was quenched with 8.7 g sodium carbonate to pH 8 and 100 mL water was added to the reaction mixture. Di-tert.butyl-dicarbonate was added to the reaction mixture and stirred over night. The solution was extracted with 50% ethyl acetate in hexane. The extracted organic layer was dried, concentrated under reduced pressure and purified by column chromatography to afford 8.0 g of the desired product. (M+H)+= 284
-
- 5 g phenylboronic acid in 30 mL dioxane was added to 3.2 g 3-chloro-5, 6, 8, 9-tetrahydro-1, 2, 7-triaza-benzocycloheptene-7-carboxylic acid tert-butyl ester and 388 mg (1,1'-bis (diphenyl-phosphinoferrocene)palladium(II)dichloride in 50 mL dioxane under argon. The reaction was stirred at 90 °C over night. The mixture was cooled to RT diluted with water and extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydroxide and brine. The solvent was removed and the precipitate was purified by column chromatographie to yieled 5.5 g of the desired product. (M+H)+= 325
-
- 40 mL hydrogen chloride in dioxane was added to 5.5 g 3-phenyl-5, 6, 8, 9-tetrahydro-1, 2, 7-triaza-benzocycloheptene-7-carboxylic acid tert-butyl ester in 40 mL dioxane at 5 °C. The reaction was stirred over night. The solvent was removed and co-evaporated with ethyl acetate to yield 3.7 g of the desired product. Rt: 4.09 min (method AE), (M+H)+: 226
-
-
- 36 mL acetic acid was added to 10.5 g 4-carboxymethyl-5-oxo-azepane-1-carboxylic acid tert-butyl ester in 75 mL THF at 5 °C. 3.1 mL methylhydrazine was added to the mixture and refluxed for 3h. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine. The crude product was purified by column chromatography on silica gel to yield 6.9 g of the desired product. (M+H)+: 282
-
- 3g DDQ was added to 2.5 g 2-methyl-3-oxo-2, 3, 4, 4a, 5, 6, 8, 9-octahydro-1, 2, 7-triaza-benzocycloheptene-7-carboxylic acid tert-butyl ester in 25 mL dioxane. The reaction was refluxed for 12h. Then aqueous potassium carbonate solution was added and the mixture was extracted with chloroform. The organic layer was washed with brine. The crude product was purified by column chromatography on silica gel to yield 1.3 g of the desired product. (M+H)+: 280
-
- 40 mL dioxane solution of hydrogen chloride was added to 5.5 g 3-phenyl-5, 6, 8, 9-tetrahydro-1, 2, 7-triaza-benzocycloheptene-7-carboxylic acid tert-butyl ester in 40 mL dioxane at 5 °C. The reaction was stirred over night. The solvent was removed and co-evaporated with ethyl acetate to yield 3.7 g of the desired product. (M+H)+: 180, Rt: 7.84 min (method AE)
-
-
- 9.8 mL bromine was added to 30 g 7-methyl-azepan-4-one hydrobromide in 180 mL acetic acid. The reaction was stirred over night at RT. The reaction was evaporated to yield 33 g of the desired product as isomere mixture. Rf: 0.4 (DCM/ MeOH= 20/1), (M+H)+= 206
-
- A mixture of 33 g 5-bromo-7-methyl-azepan-4-one hydrobromide and 3-bromo-7-methylazepan-4-one hydrobromide and 8.6 g thioacetamide in 400 mL dry EtOH was refluxed overnight. The reaction mixture was concentrated to give 30 g of the desired product, which was used for the next step without further purification. Rf: 0.2 (DCM/ MeOH= 20/1), (M+H)+= 183
-
- A mixture of 30 g 2, 7-dimethyl-5, 6, 7, 8-tetrahydro-4H-thiazolo [4, 5-d] azepine hydrobromide and 2, 6-dimethyl-5, 6, 7, 8-tetrahydro-4H-thiazolo [5, 4-c] azepine hydrobromide, 38.5 g di-tert.butyl-dicarbonate and 9.1 g sodium hydroxide in 300 mL water and 500 mL tetrahydrofuran was stirred at RT for 3 h. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and evaporated to dryness. The residue was purified by pre-HPLC to give 7.7 g of the desired product. Rf: 0.6 (DCM/MeOH=20/1), (M+H)+= 283
-
- 54 ml 4 mol/L HCL in ethyl acetate was added to 7.7 g 2, 7-Dimethyl-4, 5, 7, 8-tetrahydrothiazolo [4,5-d] azepine-6-carboxylic acid tert-butyl ester in 100 mL ethyl acetate. The reaction was stirred 2h at RT and evaporated to give 6.2 g of the desired product.
Rf: 0.2 (DCM/MeOH=20/1), (M+H)+= 183 -
-
- 77 mL phosphoroxychloride was added to 62 mL DMF at 8-18 °C. 84 mL dichlormethane was added and 50 g 1-benzyl 4-azepanone hydrochloride. The reaction was stirred over night at RT. The mixture was added to 300 mL ice water and extracted with dichlormethane. The organic layer was evaporated to give 23.3 g of the desired product. (M+H)+= 287
-
Rf: 0.55 (DCM/ MeOH/ammonia= 19/1/0.1), (M+H)+= 331 -
- 150 mg (7-benzyl-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-d] azepin-2-yl)-phenyl-amine and 20 mg palladium on charcoal in 10 mL was stirred 1day under 3 bar of a hydrogen atmosphere. The mixture was filltered and evaporated to yield 84 mg of the desired product. (M+H)+=241
-
-
- 0.38 g trimethyl-oxonium tetrafluoro borate was added to 0.5 g 5-oxo-perhydro-1, 4-diazepine-1-carboxylic acid tert-butyl ester in 15 mL THF. The reaction was stirred over night at RT. The reaction mixture was washed with saturated aqueous sodiumhydrogencarbonate solution and water. The organic layer was dried and evaporated to give 428 mg of the desired product.
(M+H)+: 229, Rt: 0.82 min (method J) -
- 0.6 mL propargylamin was added to 429 mg 5-oxo-[1, 4] diazepane-1-carboxylic acid tert-butyl ester in 20 mL methanol. The reaction was refluxed 5h and evaporated to give 468 mg of the desired product. (M+H)+: 252, Rt: 0.88 min (method J)
-
- 1.89 g 3-methyl-5, 6, 8, 9-tetrahydro-imidazo [1, 2-a] [1, 4] diazepine-7-carboxylic acid tert-butyl ester was stirred in 40 mL 4 mol/L HCl solution in dioxane over night. The mixture was concentrated to give 1.67 g of the desired product. Rt: 0.62 min (method AC), (M+H)+: 152
-
-
- 2.75 mL acetanhydride was added to 5 g 3-trifluoracetyl-7-amino-1, 2, 4, 5-tetrahydro-benzo [D] azepine in concentrated acetic acid. The mixture was stirred 17 h at RT, diluted with water and stirred for another 1h at RT. The precipitate was filltered, washed with water and dried to give 5.35 g of the desired product. Rf: 0.46 (DCM/ MeOH= 19/1), (M+H)+= 301
-
- 29.2 g potassiumcarbonate in 100 mL of water was added to 17.5 g N-[3-(2, 2, 2-Trifluoroacetyl)-2, 3, 4, 5-tetrahydro-1H-benzo[d]azepin-7-yl]-acetamide in 400 mL MeOH and 50 mL THF at 5 °C. The reaction mixture was stirred in the ice bath for 2 h and 2 h at RT. The solvent was removed and the residue was extracted with brine and dichloromethane, the organic fraction was dried and the solvent removed to yield 14.9 g of the desired product.
Rf: 0.12 (DCM/ MeOH= 9/1), (M+H)+= 205 -
-
- 11.4 g sodium nitrite in water was added to 20 g Amino-acetic acid ethyl ester hydrochloride and 5.88 g sodium acetate in 50 mL water at 0 °C. The reaction was stirred 10 min. at RT. 3 mL of 10% sulfuric acid was added and the mixture was extracted with ethyl acetate. The organic layer was washed with 10% sodium carbonate, dried and evaporated to give 9 g of the desired product. Rf: 0.40 (petrol ether / ethyl acetate= 6/4), (M+H)+= 116
-
- 3 mL boron trifluoride etherate was added to 4 g 4-oxo-piperidine-1-carboxylic acid tert-butyl ester in 30 mL diethyl ether at -30 °C. Then 3.5 g diazo-acetic acid ethyl ester in diethyl ether was added at the same temperature and stirred for 30 min. The reaction was poured in to ice water and the organic layer was seperated, washed with aqueous sodiumcarbonate solution, dried and evaporated to give 3 g of the desired product.
Rf: 0.20 (petrol ether/ethyl acetate= 6/4), (M+H)+= 286 -
- 20 g 5-Oxo-azepane-1, 4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester was stirred over night at 110 °C in 200 mL 6 M hydrochloric acid. The reaction was concentrated to yield 11 g of the desired product. Rf: 0.20 (dichlormethane/methanol = 9/1), (M+H)+= 114
-
- 6 mL benzyl bromide was added to 5 g azepane-4-one hydrochloride and 18.5 g potasium carbonate in 50 mL THF and 25 mL water. The mixture was stirred 5h at 50 °C, evporated, diluted with water and extracted with ethyl acetate. The organic layer was evaporated. The residue was purified by chromatographie on silica gel (petrolether/ ethyl acetate:8/2) to give 5 g of the desired product. Rf: 0.40 (hexane/ethyl acetate= 1/1), (M+H)+= 204
-
- 33% hydrobromic acid in conc. acetic acid and 1.97 g bromine was added to 5 g 1-benzylazepane-4-one in 15 mL conc. acetic acid. The reaction was stirred 2h at RT and completely concentrated under reduced pressure. The residue was diluted with ethyl acetate and refluxed for 1h and crystallized with ethyl acetate to give 4 g of the desired product.
Rf: 0.40 (hexane/ethyl acetate= 1/1), (M+H)+= 282/84 -
- 2.7 g thiourea was added to 5 g 1-benzyl-5-bromo-azepan-4-one in 50 ml ethanol. The reaction was refluxed 5h and concentrated. The residue was diluted with water and extracted with ethyl acetate. The organic layer was concentrated to give 4 g of the desired product.
Rf: 0.4 (hexane / ethyl acetate= 1/1)
(M+H)+= 262 -
- 6 mL hydrochloric acid was added at 0 °C to 6 g 6-benzyl-5, 6, 7, 8-tetrahydro-thiazolo [4, 5-d] azepine-2-ylamine in 80 mL acetonitrile. The reaction was stirred for 15 min. and 1.9 g sodium nitrite was added. After 30 min. 2.75 g copper(I) chloride was added and the mixture was stirred 2h at RT. The reaction was evaporated, water was added and the mixture was extracted with ethyl acetate. The organic layer was evaporated. The residue was purified by chromatographie on silica gel (hexane/ethyl acetate:9/1) to give 4 g of the desired product.
Rf: 0.6 (hexane / ethyl acetate= 1/1)
(M+H)+= 281 -
- 3.87 g sodium methoxide was added to 4 g 6-Benzyl-2-chloro-5, 6, 7, 8-tetrahydro-thiazolo [4, 5-d] azepine in 40 mL methanol. The reaction was heated to 80°C in a sealed tube. After completion of the reaction the solvent was removed, water was added and extracted with ethyl acetate. The organic layer was evaporated and the residue was purified by chromatographie on silica gel (petrolether/ethyl acetate:8/2) to give 3 g of the desired product.
Rf: 0.4 (hexane / ethyl acetate= 1/1)
(M+H)+= 277 -
- 12.5 g 1-chloroethylchloroformic acid was added to 8 g 6-benzyl-2-methoxy-5, 6, 7, 8-tetrahydro-thiazolo [4, 5-d] azepine and 24 mL DIPEA in 80 mL ethyl acetate at 0 °C. The reaction was stirred 3h at RT and evaporated to give 7 g of the desired product. Rf: 0.6 (hexane/ethyl acetate= 1/1), (M+H)+= 293
-
- 7 g 2-Methoxy-5, 6, 7, 8-tetrahydro-thiazolo [4, 5-d] azepine-6-carboxylic acid 1-chloro-ethyl ester in 70 mL methanol was heated 15 min. at 40 °C and concentrated. The residue was purified by chromatography (dichlormethane/methanol:6/4) to give 4 g of the desired product.
Rf: 0.2 (DCM/ MeOH= 1/1), (M+H)+= 187 -
- 6.6 g urea was added to 6 g 5-bromo-azepan-4-one hydrobromide and heated 24 h at 70°C. 4 M aqueous sodium hydroxide was added and the mixture was extracted with chloroform and ethyl acetate. The combined organic layers were evaporated to give 800 mg of the desired product. Rt: 0.39 min (method B), (M+H)+: 154
-
- 110 g azepin-4-on hydrochloride and 99.5 g 2-aminoacetophenone was refluxed for 2 days in 1.5 L 2 M aqueous hydrochloride acid. The mixture was coolded to RT, 2 M aqueous sodium hydroxyde solution was added and the mixture was extracted with chloroform .The organic layer was dried and evaporated. The residue was purified by chromatographie on silica gel (100 % methanol) to yield 64 g of the desired product. Rf: 0.1 (methanol), (M+H)+: 213
-
-
- 12 g Benzylamine and 25 g 4-bromo-1-buten were added to a suspension of 46 g potassium carbonate in 150 mL DMF and the mixture was heated at 50 °C for 16 h. The reaction mixture was cooled to RT, diluted with ethyl acetate, washed with water and brine, dried, concentrated, and purified by chromatographie on silica gel (hexane/ ethyl acetate 50:1) to yield 18.3 g of the desired product. (M+H)+: 230
-
- 11.2 mL benzylchloroformate was added to 14 g N-benzyl-N-(but-3-enyl)-but-3-en-1-amine in 100 mL toluene at 0 °C. After being heated at 70 °C for 3 h, the reaction mixture was cooled to RT, basified with saturated aqueous sodium hydrogencarbonate solution, extracted with ethyl acetate, washed with brine, dried, concentrated, and purified by chromatographie on silica gel (hexane/ ethyl acetate 20:1) to yield 16.8 g of the desired product. (M+H)+: 274
-
- 0.15 g Grubb's 2 catalyst was added to a solution of 8 g benzyl dibut-3-enylcarbamate in 680 mL toluene and heated at 50 °C for 5 h. The solvent was removed and the residue was purified by chromatographie on silica gel (ethyl acetate/hexane 1:5) to yield 6.6 g of the desired product. (M+H)+: 232
-
- 18 g m-chloroperbenzoic acid was added to 10 g benzyl 2, 3, 6, 7-tetrahydro-1H-azepine-1-carboxylate in 250 ml dichloromethane at 0 °C in several portions. The mixture was allowed to warm to RT over 2 h. 1 L ethyl acetate was added and the solution was extracted with aqueous sodium bicarbonate, 1N aqueous sodium hydroxide and brine. The organic layer was evaporated and the residue was purified by chromatographie on silica gel (ethyl acetae/hexanes 1:5) to yield 10.4 g of the desired product.
-
- 3 g benzyl 8-oxa-4-azabicyclo [5.1.0] octane-4-carboxylate in 70 mL 30% aqueous ammonia was stirred at 65 °C in a sealed vessel overnight. The reaction was extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate filtered and concentrated to yield 3.1 g of the desired product. (M+H)+: 265
-
- 3 mL acetic anhydride was added to 8.4 g benzyl 4-amino-5-hydroxy-azepane-1-carboxylic acid benzyl ester in 115 ml dichloromethane at 0 °C. After 1 h at RT, saturated sodium bicarbonate was added. The phases were separated and the aqueous phase was extracted with dichloromethane. The combined organic phase was washed with brine, dried over sodium sulphate, filtered and concentrated. The residue was purified by chromatographie on silica gel (ethyl acetate/hexane 2:1) to yield 4.5 g of the desired product. (M+H)+: 307
-
- 11 g Dess Martin Periodane was added to 6.2 g 4-acetylamino-5-hydroxy-azepane-1-carboxylic acid benzyl ester in 100 mL dichloromethane and stirred for 1 h at RT. The mixture was diluted with dichloromethane and washed with 2 mol/L sodium hydroxide solution. The organic layere was washed with brine, dried and concentrated. The residue was purified by chromatographie on silica gel (EtOAc) to yield 5.5 g of the desired product. (M+H)+: 305
-
- 3 g 4-acetylamino-5-oxo-azepane-1-carboxylic acid benzyl ester in 100 mL tetrahydrofuran and 3.8 g (methoxycarbonylsulfamoyl) triethylammonium hydroxide were heated in a sealed tube at 75 °C for 1h. The solvent was evaporated and the residue was purified by chromatographie on silica gel (ethyl acetate/ hexane 1:2) to yield 23 g of the desired product. (M+H)+: 287
-
- A solution of 25 g of benzyl 2-methyl-4, 5, 7, 8-tetrahydrooxazolo [4, 5-d] azepine-6-carboxylate in 500 ml 2-propanol was stirred under hydrogen atmosphere (1 atm) in the presence of 450 mg of 5% palladium/charcoal (50% water) at RT overnight. After filtration over celite the filtrate was concentrated. The residue was diluted in a mixture of dichloromethane and diethylether and 2 mol/L hydrochloric acid in diethylether was added. The precipitate was filtered and dried to yield 15.5 g of the desired product. Rt: 0.86 min (method F), (M+H)+: 153
-
- 9.27 g KOtBu was added to 109 mg 18-Krone-6 and 5 mL 4-fluoracetophenone in 150 mL THF. After 30 min at RT 10.7 g 4-fluoro-benzoic acid methyl ester was added and stirred for 3 h at RT. The reaction was decomposed with water and filtered, the filtrate was concentrated and the residue was purified by chromatography on silica gel (cyclohexane/EE: 98:2). The solvent was removed and 3.9 g of the desired compound was obtained. (M+H)+: 261. 1H-NMR ,DMSO 8,30-8,23 (m,3H, 3/CH), 8,10-8,01 (m, 1H, CH), 3,88-3,85 (s, 1H, CH2)
- By using the same synthesis strategy as for 1, 3-Bis-(4-fluoro-phenyl)-1, 3- propandione the following compounds were obtained:
Examples Product MS m/z [M+H] + HPLC Method Rt min 6.02.01.02 209 method C 1.05 6.02.01.03 195 method C 1.00 6.02.01.04 221 method J 1.48 6.02.01.05 239 1H-NMR : DMSO 6,60-6,56 (s,1H,CH), 2,71-2,63 (m,1H,CH), 1,18-1,15 (d,6H,2/CH3) 6.02.01.06 223 method J 1.59 6.02.01.07 243 method D 1.08 6.02.01.08 262 method D 1.09 6.02.01.09 225 method T 1.20 6.02.01.10 191 method U 0.81 6.02.01.11 205 method U 0.86 6.02.01.12 195 method S 1.20 6.02.01.13 257 method I 1.16 6.02.01.14 211/13 method U 0.89 6.02.01.15 195 method S 1.20 6.02.01.16 240 method S 1.02 6.02.01.17 259 method W 1.69 6.02.01.18 258 method W 1.63 6.02.01.19 258 Method W 1.64 6.02.01.20 239 method T 1.56 6.02.01.21 224 method AB 0.94 6.02.01.22 209 method A 0.96 6.02.01.23 269 method R 1.66 6.02.01.24 292 method AB 0.97 6.02.01.25 257 method A 1.05 6.02.01.26 275 method A 1.00 -
- 17.3 g KOtBu was dissolved in 500 mL THF and 9 mL acetophenone was added. After 15 min at RT 25.9 g 4-fluoro-3-mehyl-benzoic acid methyl ester was added and stirred for 3 h at RT. The solvent was removed and the residue was purified by chromatography on silica gel (cyclohexane/EE: 98:2). After combination of the desired fractions and removal of the solvent 19.3 g of the desired compound was obtained. (M+H)+: 257
- By using the same synthesis strategy as for 1-(4-fluoro-3-mehyl-phenyl)-3-phenyl-1, 3-propanedione the following compounds were obtained:
Examples Product MS m/z [M+H] + HPLC Method Rt min 6.02.01.22 223 method I 1.03 6.02.01.23 221 method J 1.53 6.02.01.24 235 1H-NMR: 6.48(s,1H,CH), 3.88(s,3H,CH3), 2.20(s,3H,CH3) 6.02.01.25 263 method J 1.73 6.02.01.26 261 method J 1.67 6.02.01.27 223 method I 1.03 6.02.01.28 209 method I 1.45 6.02.01.29 253 method I 1.06 6.02.01.30 253 method W 1.50 6.02.01.31 240 method I 1.02 6.02.01.32 237 method W 1.67 6.02.01.33 254 method I 0.98 6.02.01.34 205 method U 0.89 6.02.01.35 254 method I 0.98 6.02.01.36 223 method W 1.63 6.02.01.37 273 method I 1.00 6.02.01.38 250 method Y 1.58 6.02.01.39 202 method Y 1.38 -
- 3.9 g 1, 3-Bis-(4-fluoro-phenyl)-1, 3- propandione was dissolved in 45 mL of a solution of 1 N hydrazine in THF and stirred for 2 h at 75 °C. The solvent was removed to give 3.6 g of the desired compound. Rt: 1.03 min (method D), (M+H)+: 257
- By using the same synthesis strategy as for 3, 5-Bis-(4-fluoro-phenyl)-1H-pyrazole the following compounds were obtained:
Examples Product MS m/z [M+H]+ HPLC Method Rt min 6.02.02.02 253 method D 1.07 6.02.02.03 206 method C 0.93 6.02.02.04 191 method C 0.87 6.02.02.05 219 method I 0.93 6.02.02.06 217 method J 1.38 6.02.02.07 217 method J 1.27 6.02.02.08 231 method J 1.54 6.02.02.09 259 method J 1.39 6.02.02.10 335 method J 1.35 6.02.02.11 257 method J 1.51 6.02.02.12 219 method J 1.44 6.02.02.13 240 method D 0.97 6.02.02.14 258 method D 0.95 6.02.02.15 221 method S 1.10 6.02.02.16 219 method I 0.93 6.02.02.17 205 method T 1.26 6.02.02.18 187 method T 1.20 6.02.02.19 201 method U 0.71 6.02.02.20 249 method I 1.06 6.02.02.21 191 method S 1.10 6.02.02.22 253 method I 0.99 6.02.02.23 249 method U 0.76 6.02.02.24 207 method U 0.81 6.02.02.25 236 method I 0.68 6.02.02.26 233 method W 1.52 6.02.02.27 250 method I 0.64 6.02.02.28 201 method U 0.78 6.02.02.29 308 method I 0.69 6.02.02.30 219 method W 1.45 6.02.02.31 236 method S 0.84 6.02.02..32 255 method W 1.50 6.02.02.33 269 method Z 0.76 6.02.02.34 254 method W 1.35 6.02.02.35 254 method W 1.39 6.02.02.36 198 method Y 1.24 6.02.02.37 246 method Y 1.41 6.02.02.38 235 method U 0.85 6.02.02.39 220 method AB 0.78 6.02.02.40 205 method T 0.86 6.02.02.41 265 method Y 1.51 6.02.02.42 288 method AB 0.85 6.02.02.43 253 method Y 0.97 6.02.02.44 271 method Y 0.95 -
- 983 mg hydrazine acetate was added to 2 g 2, 4-Dioxo-4-phenyl-butyric acid methyl ester in 10 mL concentrated acetic acid. The mixture was stirred over night at RT. Then water was added. The precipitate was filtered, stirred with diisopropylether and again filtered to give 1.3 g desired product. Rt: 1.39 min (method O), (M+H)+: 203
-
- 3.6 g 3,5-Bis-(4-fluoro-phenyl)-1H-pyrazole, 8.8 g K2CO3 and 1.34 mL 2-bromoacetic acid methyl ester were dissolved in 100 mL acetone and stirred over night under reflux. K2CO3 was filtered and the solvent was removed. The residue was purified by HPLC (method 1) to yield 2.6 g of the desired product.
- By using the same synthesis strategy as for 3-(4-fluoro-3-mehyl-phenyl)-5-phenyl-pyrazol-1-yl-acetic acid methyl ester the following compounds were obtained:
Examples Product MS m/z [M+H] + HPLC Method Rt min 6.02.03.02 325 method I 0.97 6.02.03.03 277 method C 0.98 6.02.03.04 263 method C 0.92 6.02.03.05 291 method I 0.97 6.02.03.06 289 method J 1.41 6.02.03.07 289 method J 1.36 6.02.03.08 289 method J 1.54 6.02.03.09 331 method J 1.62 6.02.03.10 307 method L 1.39 6.02.03.11 329 6.02.03.12 291 method J 1.47 6.02.03.13 312 method D 0.99 6.02.03.14 330 method D 1.01 6.02.03.15 293 method S 1.20 6.02.03.16 291 method I 0.97 6.02.03.17 291 method T 1.33 6.02.03.18 259 method U 0.81 6.02.03.19 273 method T 1.42 6.02.03.20 321 method I 1.07 6.02.03.21 263 method V 1.20 6.02.03.22 325 method I 0.97 6.02.03.23 321 method U 0.80 6.02.03.24 279 method U 1.44 6.02.03.25 308 method I 0.66 6.02.03.26 305 method W 1.56 6.02.03.27 322 method I 0.64 6.02.03.28 273 method W 1.50 6.02.03.29 322 method I 0.71 6.02.03.30 291 method W 1.53 6.02.03.31 308 method V 0.85 6.02.03.32 327 method W 1.55 6.02.03.33 341 method AA 0.79 6.02.03.34 326 method W 1.34 6.02.03.35 326 method W 1.38 6.02.03.36 270 method AC 1.26 6.02.03.37 318 method AB 1.39 6.02.03.38 307 method X 1.53 6.02.03.39 277 method AD 0.90 6.02.03.40 292 method AB 0.82 6.02.03.41 360 method AB 0.86 6.02.03.43 337 method AB 1.51 6.02.03.44 325 method AB 0.98 6.02.03.45 343 -
- 3.6 g of 3-(4-fluoro-3-mehyl-phenyl)-5-phenyl-pyrazol-1-yl-acetic acid methyl ester was dissolved in 20 mL dioxane and a solution of 292 mg LiOH in 3 mL of water was added. The mixture was stirred over the weekend at RT. The solvent was removed and the residue was dissolved in 2M HCl and stirred for 2h. The solvent was removed to yield 2.4 g of the product. Rt: 1.43 (method E), (M+H)+: 315
- By using the same synthesis strategy as for (3, 5-Bis-(4-fluoro-phenyl)-pyrazol-1-yl)-acid the following compounds were obtained:
Examples Product MS m/z [M+H]+ HPLC Method Rt min 6.02.04.02 311 method D 1.05 6.02.04.03 263 method C 0.93 6.02.04.04 249 method C 0.87 6.02.04.05 277 method I 0.90 6.02.04.06 275 method J 1.05 6.02.04.07 275 method J 1.30 6.02.04.08 289 method J 1.39 6.02.04.09 317 method J 1.58 6.02.04.10 293 method N 1.04 6.02.04.11 315 1H-NMR: 6.57(s,1H,CH), 4.95(s,2H,CH2), 3.80(s,3H,CH3) 6.02.04.12 277 method J 1.45 6.02.04.13 298 method D 0.90 6.02.04.14 316 method E 1.33 6.02.04.15 279 method R 1.40 6.02.04.16 277 method I 0.90 6.02.04.17 263 method U 0.78 6.02.04.18 245 method T 1.25 6.02.04.19 259 method T 1.32 6.02.04.20 307 method I 0.97 6.02.04.21 249 method V 1.20 6.02.04.22 311 method I 0.95 6.02.04.23 307 method U 0.75 6.02.04.24 265 method W 1.38 6.02.04.25 294 method I 0.65 6.02.04.26 291 method U 0.85 6.02.04.27 308 method I 0.65 6.02.04.28 259 method W 1.41 6.02.04.29 308 method Y 0.91 6.02.04.30 277 method W 1.45 6.02.04.31 294 method S 0.80 6.02.04.32 313 method W 1.51 6.02.04.33 327 method I 0.87 6.02.04.34 312 method W 1.26 6.02.04.35 312 method W 1.30 6.02.04.36 256 method AB 0.88 6.02.04.37 304 method AB 1.02 6.02.04.38 293 method U 0.97 6.02.04.39 263 method Y 0.86 6.02.04.40 278 method AB 0.76 6.02.04.41 346 method AB 0.81 6.02.04.42 323 method M 1.46 6.02.04.43 311 method M 0.95 6.02.04.44 329 method M 0.68 -
- 28 mg (3, 5-diphenyl-pyrazol-1-yl)-acetic acid was dissolved in 2 mL DMF and 26 mg DIPEA and 32 mg TBTU were added to this solution and the reaction was stirred for 5 minutes at RT. The mixture was added to 20 mg 5-chloro-2-piperidin-4-ylpyrimidine and stirred for 2h. The reaction was cleaned by RP- chromatographie (methanol/water, 0.1%NH3) to yield 11 mg of the desired compound. Rt: 2.38 (method A), (M+H)+: 458
- By using the same synthetic strategy as for 2-(3, 5-diphenyl-pyrazol-1-yl)-1-(4-(5-chloro-pyrimidin-2-yl)-1-piperidinyl)-ethanon the following compounds were obtained:
Examples Product MS m/z [M+H] + HPLC Method Rt min 7.01.002 399 method B 2.15 7.01.003 444 method A 2.09 7.01.004 410 method B 2.33 7.01.005 401 method A 2.35 7.01.006 398 method A 2.19 7.01.007 424 method B 2.37 7.01.008 438 method B 2.39 7.01.009 412 method A 2.41 7.01.010 462 method B 2.46 7.01.011 467 method A 2.31 7.01.012 499 method A 2.33 7.01.013 515 method A 2.36 7.01.014 455 method A 2.32 7.01.015 424 method A 2.44 7.01.016 464 method A 2.40 7.01.017 415 method B 1.69 7.01.018 424 method B 2.35 7.01.019 455 method A 2.31 7.01.020 467 method A 2.27 7.01.021 472 method A 2.31 7.01.022 452 method A 2.39 7.01.23 430 method G 1.86 7.01.024 430 method A 2.40 7.01.025 509 method B 2.42 7.01.026 486 method A 2.37 7.01.027 412 method A 2.39 7.01.028 501 method A 2.34 7.01.029 438 method A 2.37 7.01.030 466 method A 2.40 7.01.031 419 method B 2.29 7.01.032 463 method B 2.45 7.01.033 429 method B 1.83 7.01.034 455 method A 2.31 7.01.035 467 method A 2.34 7.01.036 423 method A 1.99 7.01.037 499 method A 2.33 7.01.038 401 method A 2.32 7.01.039 428 method A 2.46 7.01.040 394 method A 2.40 7.01.041 487 method A 2.31 7.01.042 499 method A 2.36 7.01.043 430 method K 1.27 7.01.044 429 method A 2.34 7.01.045 462 method A 2.44 7.01.046 420 method B 2.29 7.01.047 508 method A 2.39 7.01.048 480 method A 2.03 7.01.049 464 method A 2.02 7.01.50 464 method AH 2.02 7.01.051 465 method A 2.17 7.01.52 430 method AD 0.74 7.01.053 497 method A 2.44 7.01.054 429 method AD 0.75 7.01.055 429 method Q 1.40 7.01.056 430 method Q 1.27 7.01.057 399 method Q 1.46 7.01.058 401 method S 1.47 7.01.059 399 method S 1.10 7.01.060 400 method S 1.00 7.01.061 369 method S 1.20 7.01.062 371 method S 1.20 7.01.063 399 method S 1.40 7.01.064 444 method V 0.88 7.01.065 422 method AD 0.73 7.01.066 470 method AD 0.70 7.01.067 399 method AD 0.70 7.01.068 400 method AD 0.68 7.01.069 456 method AD 0.69 7.01.070 450 method AD 0.71 7.01.071 398 method AD 0.71 7.01.072 407 method AD 0.66 7.01.073 399 method AD 0.74 7.01.074 427 method AD 0.74 7.01.075 383 method AD 0.71 7.01.076 384 method AD 0.73 7.01.077 383 method AD 0.71 7.01.078 427 method AD 0.75 7.01.079 500 method AD 0.79 7.01.080 533 method AD 0.77 7.01.081 472 method AF 1.50 7.01.082 518 method AD 0.76 7.01.083 470 method AD 0.79 7.01.084 505 method AD 0.75 7.01.085 431 method AD 0.78 7.01.086 444 method AD 0.76 7.01.087 426 method AD 0.80 7.01.088 498 method AD 0.79 7.010.089 447 method AD 0.77 7.01.090 440 method AD 0.79 7.01.091 471 method AD 0.77 7.01.092 518 method AD 0.78 7.01.093 448 method AD 0.74 7.01.094 446 method AD 0.75 7.01.095 455 method AD 0.74 7.01.096 448 method AD 0.74 7.01.097 497 method AD 0.77 7.01.098 382 method AD 0.67 -
- 100mg (3, 5-bis-(4-fluoro-phenyl)-pyrazol-1-yl)-acetic acid was dissolved in 2 mL DMF. 165 mg PFTU and 170 µL DIPEA were added to this solution and the mixture was stirred for 15 min at RT. Then, 160 mg 5, 6, 7, 8-Tetrahydro-4H-thiazolo (4, 5-d) azepin-2-ylamine hydrobromide was added and the reaction was stirred over night. Then, K2CO3 solution (5%) and CH2Cl2 were added, the organic phase was separated and washed two times with water. The solvent was removed and the residue was purified by HPLC (method 1) to give 78 mg of the desired compound. Rt: 0.80 min (method C), (M+H)+: 466
- By using the same synthesis strategy as for 1-(2-Amino-4, 5, 7, 8-tetrahydro-thiazolo (4, 5-d) azepin-6-yl)-2-[3,5-bis-(4-fluoro-phenyl)-pyrazol-1-yl]-ethanone the following compounds were obtained:
7.02.002 488 method A 2.09 7.02.003 437 method A 2.06 7.02.004 415 method A 2.04 7.02.005 472 method A 2.16 7.02.006 454 method A 2.10 7.02.007 463 method A 2.13 7.02.008 441 method A 2.11 7.02.009 464 method A 2.13 7.02.010 465 method C 0.95 7.02.011 437 method C 0.99 7.02.012 503 method C 0.98 7.02.013 455 method I 0.83 7.02.014 454 method I 0.98 7.02.015 461 method I 0.95 7.02.016 456 method I 0.97 7.02.017 488 method I 0.99 7.02.018 502 method I 1.00 7.02.019 460 method I 0.94 7.02.020 433 method I 0.98 7.02.021 486 method I 0.99 7.02.022 484 method I 1.00 7.02.023 462 method I 0.80 7.02.024 413 method C 0.83 7.02.025 385 method C 0.87 7.02.026 414 method C 0.74 7.02.027 451 method C 0.96 7.02.028 437 method C 0.92 7.02.029 399 method I 0.81 7.02.030 400 method I 0.68 7.02.031 371 method C 0.81 7.02.032 465 method I 1.01 7.02.033 428 method I 0.85 7.02.034 399 method I 1.01 7.02.035 425 method M 0.54 7.02.036 426 method M 0.50 7.02.037 440 method L 1.30 7.02.038 425 method J 1.30 7.02.039 420 method J 1.45 7.02.040 406 method J 1.44 7.02.041 463 method J 1.35 7.02.042 426 method J 1.20 7.02.043 395 method J 1.35 7.02.044 434 method J 1.48 7.02.045 397 method J 1.35 7.02.046 440 method J 1.31 7.02.047 439 method J 1.38 7.02.048 467 method J 1.57 7.02.049 482 method L 1.46 7.02.050 468 method J 1.47 7.02.051 443 method L 1.33 7.02.052 466 method J 1.37 7.02.053 503 method J 1.50 7.02.054 428 method J 1.34 7.02.055 427 method J 1.44 7.02.056 448 method C 0.75 7.02.057 421 method C 0.90 7.02.058 449 method C 0.67 7.02.059 439 method C 0.92 7.02.060 467 method C 0.72 7.02.061 466 method I 0.82 7.02.062 444 method L 1.25 7.02.063 451 method A 2.08 7.02.064 496 method I 0.73 7.02.065 447 method U 0.81 7.02.066 397 method U 0.74 7.02.067 427 method I 1.00 7.02.068 452 method I 1.04 7.02.069 452 method I 1.04 7.02.070 450 method I 1.06 7.02.071 450 method I 1.06 7.02.072 413 method U 0.79 7.02.073 414 method U 0.72 7.02.074 410 method U 0.75 7.02.075 381 method U 0.85 7.02.076 432 method U 0.88 7.02.077 434 method U 0.85 7.02.078 432 method U 0.88 7.02.079 396 method U 0.70 7.02.080 367 method U 0.80 7.02.081 420 method U 0.82 7.02.082 418 method U 0.84 7.02.083 409 method U 0.81 7.02.084 395 method U 0.77 7.02.085 456 method I 1.00 7.02.086 457 method I 1.00 7.02.087 480 method I 1.06 7.02.088 482 method I 1.04 7.02.089 480 method I 1.05 7.02.090 429 method F 1.53 7.02.091 482 method I 1.04 7.02.092 434 method U 0.84 7.02.093 418 method U 0.83 7.02.094 458 method I 0.86 7.02.095 461 method I 0.96 7.02.096 468 method I 0.99 7.02.097 431 method I 0.99 7.02.098 459 method I 1.01 7.02.099 472 method I 1.04 7.02.100 457 method I 1.02 7.02.101 484 method I 1.03 7.02.102 468 method I 1.03 7.02.103 457 method U 0.77 7.02.104 458 method U 0.69 7.02.105 429 method U 0.79 7.02.106 445 method X 0.85 7.02.107 411 method X 0.84 7.02.108 413 method X 0.83 7.02.109 415 method X 0.77 7.02.110 416 method X 0.69 7.02.111 387 method X 0.81 7.02.112 415 method X 0.73 7.02.113 415 method X 0.73 7.02.114 454 method I 1.00 7.02.115 454 method I 0.97 7.02.116 444 method I 0.70 7.02.117 445 method I 0.59 7.02.118 416 method I 0.72 7.02.119 441 method U 0.86 7.02.120 442 method U 0.77 7.02.121 413 method U 0.88 7.02.122 458 method I 0.68 7.02.123 459 method I 0.58 7.02.124 430 method I 0.71 7.02.125 381 method U 0.82 7.02.126 458 method I 0.70 7.02.127 459 method I 0.61 7.02.128 430 method I 0.73 7.02.129 409 method U 0.80 7.02.130 446 method U 0.90 7.02.131 441 method U 0.86 7.02.132 427 method U 0.80 7.02.133 428 method U 0.71 7.02.134 473 method I 1.00 7.02.135 425 method I 0.95 7.02.136 482 method I 1.04 7.02.137 434 method I 1.00 7.02.138 464/466 method X 0.70 7.02.139 462 method X 0.78 7.02.140 475 method I 0.98 7.02.141 427 method I 0.93 7.02.142 459 method X 0.84 7.02.143 435 method X 0.82 7.02.144 461 method X 0.83 7.02.145 463/465 method X 0.80 7.02.146 484 method I 1.03 7.02.147 436 method I 0.99 7.02.148 477 method I 0.86 7.02.149 478 method I 0.74 7.02.150 449 method I 0.91 7.02.151 476 method I 0.87 7.02.152 475 method I 0.92 7.02.153 473 method I 0.93 7.02.154 399 method I 0.84 7.02.155 355 method I 0.85 7.02.156 355 method I 0.85 7.02.157 412 method U 0.71 7.02.158 476 method U 0.73 7.02.159 531 method U 0.84 7.02.160 475 method U 0.79 7.02.161 477 method U 0.84 7.02.162 483 method U 0.80 7.02.163 427 method U 0.73 7.02.164 428 method U 0.93 7.02.165 460 method AB 1.51 7.02.166 426 method AB 1.49 7.02.167 412 method AB 1.45 7.02.168 398 method AB 1.39 7.02.169 461 method I 0.97 7.02.170 462 method U 0.68 7.02.171 463 method U 0.60 7.02.172 434 method U 0.72 7.02.173 418 method U 0.70 7.02.174 462 method U 0.71 7.02.175 462 method U 0.66 7.02.176 434 method U 0.69 7.02.177 418 method U 0.67 7.02.178 462 method U 0.68 7.02.179 462 method U 0.68 7.02.180 462 method U 0.65 7.02.181 399 method U 0.81 7.02.182 402 method I 0.95 7.02.183 404 method I 0.85 7.02.184 406 method I 0.77 7.02.185 407 method I 0.65 7.02.186 378 method I 0.82 7.02.187 406 method I 0.76 7.02.188 450 method I 0.91 7.02.189 454 method I 0.85 7.02.190 455 method I 0.71 7.02.191 426 method I 0.89 7.02.192 454 method I 0.83 7.02.193 453 method I 0.84 7.02.194 452 method I 0.89 7.02.195 461 method I 0.95 7.02.196 413 method I 0.90 7.02.197 442 method U 0.78 7.02.198 443 method U 0.78 7.02.199 444 method U 0.70 7.02.200 415 method U 0.81 7.02.201 468 method U 0.83 7.02.202 466 method U 0.84 7.02.203 468 method U 0.83 7.02.204 466 method U 0.83 7.02.205 409 method U 0.78 7.02.206 422 method U 0.82 7.02.207 411 method U 0.78 7.02.208 425 method U 0.81 7.02.209 427 method U 0.76 7.02.210 426 method U 0.76 7.02.211 427 method U 0.79 7.02.212 417 method AB 1.48 7.02.213 369 method AB 0.91 7.02.214 383 method AB 1.45 7.02.215 411 method U 0.78 7.02.216 462 method U 0.74 7.02.217 414 method U 0.67 7.02.218 474 method L 1.47 7.02.219 426 method L 1.37 7.02.220 413 method L 1.33 7.02.221 495 method L 1,36 7.02.222 467 method L 1.42 7.02.223 451 method L 1.40 7.02.224 495 method L 1.41 7.02.225 495 method L 1.35 7.02.226 494 method L 1.29 7.02.227 490 method L 1.43 7.02.228 442 method L 1.33 7.02.229 413 method L 1.44 7.02.230 365 method L 1.32 7.02.231 445 method I 0.89 7.02.232 473 method U 0.83 7.02.233 445 method U 0.84 7.02.234 496 method I 0,80 7.02.235 496 method I 0,84 7.02.236 496 method I 0,79 7.02.237 468 method I 0,85 7.02.238 413 method I 0,85 7.02.239 385 method I 0,90 7.02.240 473 method U 0.79 7.02.241 472 method U 0.74 7.02.242 499 method L 1.55 7.02.243 451 method L 1.48 7.02.244 452 method I 0,81 7.02.245 369 method L 7.02.246 429 method L 1.45 7.02.247 428 method I 0,79 7.02.248 400 method I 0,83 7.02.249 384 method I 0,81 7.02.250 461 method I 0,92 7.02.251 461 method I 0,94 7.02.252 433 method I 0,97 7.02.253 417 method I 0,95 7.02.255 431,12 method K 0,81 7.02.256 383,1 method K 0,73 7.02.257 435,12 method K 0,74 7.02.258 479,15 method K 0,70 7.02.259 479,13 method K 0,77 7.02.260 451,1 method K 0,77
Claims (5)
- A compound according to any of the preceding claims for use as a medicament.
- A pharmaceutical composition comprising at least one compound according to any of claims 1 to 2 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.
- A compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof for use in the treatment of psychotic disorders including schizophrenia, schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses, post stroke dementia, deficits in concentration, mild cognitive impairment, the cognitive dysfunction in Alzheimers disease, and the cognitive dysfunction of schizophrenia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12808705.3A EP2788086B1 (en) | 2011-12-05 | 2012-12-05 | Substituted pyrazoles as mglu5 receptor modulators |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11191924 | 2011-12-05 | ||
EP12808705.3A EP2788086B1 (en) | 2011-12-05 | 2012-12-05 | Substituted pyrazoles as mglu5 receptor modulators |
PCT/EP2012/074417 WO2013083591A1 (en) | 2011-12-05 | 2012-12-05 | Substituted pyrazoles as mglu5 receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2788086A1 EP2788086A1 (en) | 2014-10-15 |
EP2788086B1 true EP2788086B1 (en) | 2016-10-12 |
Family
ID=47469887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12808705.3A Active EP2788086B1 (en) | 2011-12-05 | 2012-12-05 | Substituted pyrazoles as mglu5 receptor modulators |
Country Status (4)
Country | Link |
---|---|
US (1) | US8741892B2 (en) |
EP (1) | EP2788086B1 (en) |
JP (1) | JP5820537B2 (en) |
WO (1) | WO2013083591A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) * | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
SG11201606080SA (en) | 2014-02-03 | 2016-08-30 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
WO2016033228A1 (en) * | 2014-08-28 | 2016-03-03 | Sunnylife Pharma, Inc. | Tetrahydro-azepinoquinolines as agonists of the 5-ht2c receptor |
PT3207043T (en) | 2014-10-14 | 2019-03-25 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
ES2856931T3 (en) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | ROR-gamma modulators |
EP3377482B1 (en) | 2015-11-20 | 2021-05-12 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
TWI757266B (en) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | Modulators of ror-gamma |
EA036137B1 (en) * | 2016-04-13 | 2020-10-02 | Юсб Байофарма Спрл | Tetrahydroisoquinoline derivatives |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
EP3872078A1 (en) | 2016-07-01 | 2021-09-01 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for use in the treament of depression, anxiety or panic disorders |
WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
AR112461A1 (en) | 2017-07-24 | 2019-10-30 | Vitae Pharmaceuticals Inc | PROCESSES FOR THE PRODUCTION OF SALTS AND CRYSTAL FORMS OF RORg INHIBITORS |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of ror gamma |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8720693D0 (en) | 1987-09-03 | 1987-10-07 | Glaxo Group Ltd | Chemical compounds |
TW533205B (en) | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
US6166008A (en) * | 1997-10-27 | 2000-12-26 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
HUP9902721A2 (en) | 1997-11-25 | 1999-12-28 | The Procter & Gamble Co. | Concentrated fabric softening composition and highly unsaturated fabric softener compound therefor |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6369222B1 (en) | 2000-07-18 | 2002-04-09 | Hoffmann-La Roche Inc. | mGluR antagonists and a method for their synthesis |
DE10130020A1 (en) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituted 1-oxa-2,8-diaza-spiro [4.5] dec-2-ene derivatives |
JP4286146B2 (en) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | Heteroaryl-substituted pyrazole modulators of metabotropic glutamate receptor-5 |
WO2003053922A2 (en) | 2001-12-19 | 2003-07-03 | Merck & Co., Inc. | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
DE10211770A1 (en) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Novel substituted piperidines, pharmaceutical compositions containing them and processes for their preparation |
CN1867336B (en) | 2002-06-12 | 2010-05-12 | 凯莫森特里克斯股份有限公司 | 1-aryl-4-substituted piperazines derivatives and pharmaceutical use thereof |
US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
MXPA05012082A (en) | 2003-05-09 | 2006-02-22 | Pharmacia & Upjohn Co Llc | Compounds as crf1 receptor antagonists. |
WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
CA2556944C (en) | 2004-03-05 | 2012-10-09 | Taisho Pharmaceutical Co., Ltd. | Thiazole derivative |
TW200800946A (en) | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Substituted piperazines as metabotropic glutamate receptor antagonists |
TW200734313A (en) | 2006-01-17 | 2007-09-16 | Astrazeneca Ab | Piperazines and piperidines as mGluR5 potentiators |
DE102006019255A1 (en) | 2006-04-26 | 2007-10-31 | Dr.Ing.H.C. F. Porsche Ag | Method and controller for adjusting a variable turbocharger turbine flow area |
US20100144710A1 (en) | 2007-03-09 | 2010-06-10 | Astrazeneca Ab | Piperazine and Piperidine MGLUR5 Potentiators |
JP5615700B2 (en) | 2007-05-25 | 2014-10-29 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Heterocyclic compounds as positive regulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
JP5443342B2 (en) | 2007-06-08 | 2014-03-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Piperidine / piperazine derivatives |
EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | Triazole derivatives for treating alzheimer's disease and related conditions |
WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
WO2010124055A1 (en) | 2009-04-23 | 2010-10-28 | Merck Sharp & Dohme Corp. | 2-alkyl piperidine mglur5 receptor modulators |
EP2424840B1 (en) | 2009-04-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Cxcr3 receptor antagonists |
WO2011002067A1 (en) | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | Heterocyclic compound and use thereof |
EP2519521B1 (en) | 2009-12-29 | 2013-11-20 | Eli Lilly and Company | Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
-
2012
- 2012-11-30 US US13/689,867 patent/US8741892B2/en active Active
- 2012-12-05 EP EP12808705.3A patent/EP2788086B1/en active Active
- 2012-12-05 WO PCT/EP2012/074417 patent/WO2013083591A1/en active Application Filing
- 2012-12-05 JP JP2014545220A patent/JP5820537B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2788086A1 (en) | 2014-10-15 |
US20130143870A1 (en) | 2013-06-06 |
JP5820537B2 (en) | 2015-11-24 |
WO2013083591A1 (en) | 2013-06-13 |
JP2015500259A (en) | 2015-01-05 |
US8741892B2 (en) | 2014-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2788086B1 (en) | Substituted pyrazoles as mglu5 receptor modulators | |
EP2788333B1 (en) | 1,2,4-triazoles as allosteric modulators of mglu5 receptor activity for the treatment of schizophrenia of dementia | |
EP2804854B1 (en) | Substituted triazoles and their use for treatment and/or prevention of neurological and psychiatric disorders | |
US8796467B2 (en) | Compounds | |
EP2785696B1 (en) | Novel compounds | |
US8883789B2 (en) | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | |
AU2008292390B2 (en) | Polycyclic compound | |
EP2791117B1 (en) | 4-aryl imidazole derivatives as mglu5 positive allesteric modulators | |
US20100168095A1 (en) | Multi-cyclic cinnamide derivatives | |
EP2791118B1 (en) | Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors | |
EP2379513A1 (en) | Heteroaryl compounds useful as raf kinase inhibitors | |
US8846948B2 (en) | Compounds | |
WO2011073172A1 (en) | Ethynyl derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140707 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20150727 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160518 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 835940 Country of ref document: AT Kind code of ref document: T Effective date: 20161015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012024119 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 835940 Country of ref document: AT Kind code of ref document: T Effective date: 20161012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170112 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170213 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170212 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012024119 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170112 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
26N | No opposition filed |
Effective date: 20170713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161205 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20121205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161012 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231220 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231221 Year of fee payment: 12 Ref country code: DE Payment date: 20231214 Year of fee payment: 12 |